Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvi

DOI: 10.1016/j.chom.2013.07.007
Cell Host and Microbe, 2013, 14, 207-15.

#	Paper	IF	Citations
1646	Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/Ecatenin signaling via its FadA adhesin. *Cell Host and Microbe*, **2013**, 14, 195-206	23.4	1082
1645	Genome-wide association and sequencing studies on colorectal cancer. **2013**, 23, 502-11		13
1644	The microbiome and cancer. **2013**, 13, 800-12		936
1643	Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. **2013**, 13, 759-71		1127
1642	Microbiota regulation of inflammatory bowel disease and colorectal cancer. **2013**, 23, 543-52		40
1641	Fusobacterium spp. and colorectal cancer: cause or consequence?. **2013**, 21, 506-8		46
1640	Microbes and inflammation in colorectal cancer. **2013**, 1, 150-7		43
1639	Need for prospective cohort studies to establish human gut microbiome contributions to disease risk. **2013**, 105, 1850-1		10
1638	Focus on gastrointestinal and liver cancers. **2013**, 23, 469-70		4
1637	Identification and characterization of fusolisin, the Fusobacterium nucleatum autotransporter serine protease. **2014**, 9, e111329		14
1636	Fusobacterium Infections. **2014**,		0
1635	Potential of fecal microbiota for early-stage detection of colorectal cancer. **2014**, 10, 766		575
1634	Oral bacteria and cancer. **2014**, 10, e1003933		177
1633	A physicians' wish list for the clinical application of intestinal metagenomics. **2014**, 11, e1001627		8
1632	Multifunctional nutrient-binding proteins adapt human symbiotic bacteria for glycan competition in the gut by separately promoting enhanced sensing and catalysis. **2014**, 5, e01441-14		51
1631	Looking in the Porphyromonas gingivalis cabinet of curiosities: the microbium, the host and cancer association. **2014**, 29, 55-66		85
1630	The microbiome of New World vultures. **2014**, 5, 5498		177

1629 Obesity and cancer pathogenesis. **2014**, 1311, 57-76 135

1628 Microbiota organization is a distinct feature of proximal colorectal cancers. **2014**, 111, 18321-6 405

1627 Periodontal disease with treatment reduces subsequent cancer risks. **2014**, 107, 805-12 28

1626 Microbial imbalance and intestinal pathologies: connections and contributions. **2014**, 7, 1131-42 65

1625 Gut microbiome and colorectal adenomas. **2014**, 20, 225-31 70

1624 The Cancer Research Institute 2013 Annual Symposium: Dynamics of host-tumor interaction. **2014**, 2, 105-11

1623 Inflammation and colorectal cancer, when microbiota-host mutualism breaks. **2014**, 20, 908-22 137

1622 The cytolethal distending toxin effects on Mammalian cells: a DNA damage perspective. **2014**, 3, 592-615 54

1621 Microbiota and immune responses in colon cancer: more to learn. **2014**, 20, 232-6 9

1620 Microbiome and colorectal carcinoma: insights from germ-free and conventional animal models. **2014**, 20, 217-24 34

1619 The microbiome in inflammatory bowel disease: current status and the future ahead. **2014**, 146, 1489-99 1055

1618 Beneficial modulation of the gut microbiota. **2014**, 588, 4120-30 166

1617 Role of the microbiota in immunity and inflammation. **2014**, 157, 121-41 2330

1616 Gastrointestinal malignancy and the microbiome. **2014**, 146, 1534-1546.e3 195

1615 The multifaceted role of the intestinal microbiota in colon cancer. **2014**, 54, 309-20 215

1614 From promotion to management: the wide impact of bacteria on cancer and its treatment. **2014**, 36, 658-64 7

1613 The fire within: microbes inflame tumors. **2014**, 157, 776-83 90

1612 Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics. **2014**, 18, 402-14 89

1611	Gut microbiota in older subjects: variation, health consequences and dietary intervention prospects. **2014**, 73, 441-51		28
1610	Specialized metabolites from the microbiome in health and disease. **2014**, 20, 719-730		337
1609	Obesity-associated gastrointestinal tract cancer: from beginning to end. **2014**, 120, 935-9		10
1608	Cancer-promoting effects of microbial dysbiosis. **2014**, 16, 406		132
1607	Microbial determinants of biochemical individuality and their impact on toxicology and pharmacology. **2014**, 20, 761-768		43
1606	Mobile elements and viral integrations prompt considerations for bacterial DNA integration as a novel carcinogen. **2014**, 352, 137-44		11
1605	The human gut microbiome as a screening tool for colorectal cancer. **2014**, 7, 1112-21		316
1604	Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. **2014**, 109, 1205-14		42
1603	Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. **2014**, 5, 4724		222
1602	The gut microbiota, bacterial metabolites and colorectal cancer. **2014**, 12, 661-72		1390
1601	Structure of the gut microbiome following colonization with human feces determines colonic tumor burden. **2014**, 2, 20		176
1600	Human fecal microbiome-based biomarkers for colorectal cancer. **2014**, 7, 1108-11		30
1599	Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. **2014**, 33, 1381-90		279
1598	Anatomical localization of commensal bacteria in immune cell homeostasis and disease. **2014**, 260, 35-49		46
1597	Microbes, microbiota, and colon cancer. *Cell Host and Microbe*, **2014**, 15, 317-28	23.4	504
1596	Fusobacterium and Enterobacteriaceae: important players for CRC?. **2014**, 162, 54-61		89
1595	Microbiota in the Throat and Risk Factors for Laryngeal Carcinoma. **2014**, 80, 7356-63		35
1594	Commentary: Oral bacteria as drivers for colorectal cancer. **2014**, 85, 1155-7		12

1593	Animal models of gastrointestinal and liver diseases. New mouse models for studying dietary prevention of colorectal cancer. **2014**, 307, G249-59	7
1592	Candida albicans and cancer: Can this yeast induce cancer development or progression?. **2016**, 42, 181-93	63
1591	Intestinal dysbiosis: novel mechanisms by which gut microbes trigger and prevent disease. **2014**, 65, 133-7	37
1590	Recent advancement in understanding colitis-associated tumorigenesis. **2014**, 20, 2115-23	17
1589	Malignant Tumors of the Colon. **2015**, 1554-1582	
1588	Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity. **2015**, 5, 16865	191
1587	A holo'ome approach in colon cancer: we change as we age. **2015**, 16, 1239-40	2
1586	[Gut Microbiota and Internal Diseases: Update Information. Topics: V. Gut Microbiota: Topics in Various Medical Fields; 4. Interactions between the host immune system and microbes]. **2015**, 104, 81-5	
1585	Fecal microbiota transplantation broadening its application beyond intestinal disorders. **2015**, 21, 102-11	142
1584	Context and the human microbiome. **2015**, 3, 52	58
1583	Microbiome changes associated with sustained eradication of Clostridium difficile after single faecal microbiota transplantation in children with and without inflammatory bowel disease. **2015**, 42, 741-52	55
1582	Fusobacterium nucleatum: an emerging bug in colorectal tumorigenesis. **2015**, 24, 373-85	42
1581	Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment. **2015**, 6, 32013-26	70
1580	Towards large-cohort comparative studies to define the factors influencing the gut microbial community structure of ASD patients. **2015**, 26, 26555	13
1579	Red Meat and Colorectal Cancer. **2015**, 9, 288	63
1578	Changes in microflora in dental plaque from cancer patients undergoing chemotherapy and the relationship of these changes with mucositis: A pilot study. **2015**, 20, e259-66	2
1577	Periodontal pathogens Porphyromonas gingivalis and Fusobacterium nucleatum´promote tumor progression in an oral-specific chemical carcinogenesis model. **2015**, 6, 22613-23	185
1576	Oral microbiome and history of smoking and colorectal cancer. **2016**, 2, 92-101	45

1575	Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. **2015**, 6, 7209-20		183
1574	Bacteroides, Prevotella, Porphyromonas, and Fusobacterium Species (and Other Medically Important Anaerobic Gram-Negative Bacilli). **2015**, 2773-2780		9
1573	Quantitative profiling of colorectal cancer-associated bacteria reveals associations between fusobacterium spp., enterotoxigenic Bacteroides fragilis (ETBF) and clinicopathological features of colorectal cancer. **2015**, 10, e0119462		130
1572	Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. **2015**, 42, 965-76		343
1571	Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. **2015**, 1, 653-61		336
1570	Life Extension. **2015**,		0
1569	Bacteria Moving into Focus of Human Cancer. *Cell Host and Microbe*, **2015**, 17, 728-30	23.4	10
1568	Pouch Inflammation Is Associated With a Decrease in Specific Bacterial Taxa. **2015**, 149, 718-27		58
1567	Virulence genes are a signature of the microbiome in the colorectal tumor microenvironment. **2015**, 7, 55		121
1566	Group 3 innate lymphoid cells: regulating host-commensal bacteria interactions in inflammation and cancer. **2016**, 28, 43-52		18
1565	A Molecular-Level Landscape of Diet-Gut Microbiome Interactions: Toward Dietary Interventions Targeting Bacterial Genes. **2015**, 6, e01263-15		29
1564	The gastrointestinal microbiota and colorectal cancer. **2015**, 308, G351-63		121
1563	Nutrients, foods, and colorectal cancer prevention. **2015**, 148, 1244-60.e16		327
1562	Insights on the human microbiome and its xenobiotic metabolism: what is known about its effects on human physiology?. **2015**, 11, 411-25		39
1561	Intracellular colon cancer-associated Escherichia coli promote protumoral activities of human macrophages by inducing sustained COX-2 expression. **2015**, 95, 296-307		56
1560	Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. **2015**, 42, 344-355		562
1559	The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases. **2015**, 66, 343-59		240
1558	Advances in Salivary Diagnostics. **2015**,		8

1557 The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. **2015**, 5, 16-8 247

1556 Fusobacterium nucleatum: a commensal-turned pathogen. **2015**, 23, 141-7 359

1555 Microbiota-mediated inflammation and antimicrobial defense in the intestine. **2015**, 33, 227-56 167

1554 Biogeography of the intestinal mucosal and lumenal microbiome in the rhesus macaque. *Cell Host and Microbe*, **2015**, 17, 385-391 23.4 185

1553 Fap2 of Fusobacterium nucleatum is a galactose-inhibitable adhesin involved in coaggregation, cell adhesion, and preterm birth. **2015**, 83, 1104-13 115

1552 Fusobacterium and Escherichia: models of colorectal cancer driven by microbiota and the utility of microbiota in colorectal cancer screening. **2015**, 9, 651-7 28

1551 Gut microbiome development along the colorectal adenoma-carcinoma sequence. **2015**, 6, 6528 614

1550 Why do infections cause cancer?. **2015**, 21, 967-8 1

1549 Gut Microbiota and Colorectal Cancer. **2015**, 2, 26-32 39

1548 Metabolism of Chinese Materia Medica in Gut Microbiota and Its Biological Effects. **2015**, 7, 109-115 4

1547 Can we change our microbiome to prevent colorectal cancer development?. **2015**, 54, 1085-95 13

1546 CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function. **2015**, 12, 244-57 200

1545 Parallels Between Mammals and Flies in Inflammatory Bowel Disease. **2015**, 151-189 1

1544 ZnO and TiO2 nanoparticles as novel antimicrobial agents for oral hygiene: a review. **2015**, 17, 1 52

1543 New insights from animal models of colon cancer: inflammation control as a new facet on the tumor suppressor APC gem. **2015**, 39 2

1542 Multidimensional effects of biologically synthesized silver nanoparticles in Helicobacter pylori, Helicobacter felis, and human lung (L132) and lung carcinoma A549 cells. **2015**, 10, 35 113

1541 Nitric Oxide and Cancer: Pathogenesis and Therapy. **2015**, 2

1540 Gut microbiome compositional and functional differences between tumor and non-tumor adjacent tissues from cohorts from the US and Spain. **2015**, 6, 161-72 63

1539	An integrative view of microbiome-host interactions in inflammatory bowel diseases. *Cell Host and Microbe*, **2015**, 17, 577-91	23.4	178
1538	Proceedings of the second international molecular pathological epidemiology (MPE) meeting. **2015**, 26, 959-72		30
1537	The gut microbiome in health and in disease. **2015**, 31, 69-75		721
1536	Cancer and the microbiota. **2015**, 348, 80-6		623
1535	Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. **2015**, 137, 1258-68		164
1534	Autoimmune host-microbiota interactions at barrier sites and beyond. **2015**, 21, 233-44		68
1533	TLR4 activation by lipopolysaccharide confers survival advantage to growth factor deprived prostate cancer cells. **2015**, 75, 1020-33		29
1532	"Messieurs, c'est les microbes qui auront le dernier mot": Gentlemen, it is the microbes who have the last word (Louis Pasteur)- protect tumors from killing by immune cells. **2015**, 4, e1038690		4
1531	Porcine Epidemic Diarrhea Virus Infection Induced the Unbalance of Gut Microbiota in Piglets. **2015**, 71, 643-9		29
1530	The Microbiome and Cancer: Is the 'Oncobiome' Mirage Real?. **2015**, 1, 24-35		51
1529	Stool metatranscriptomics: A technical guideline for mRNA stabilisation and isolation. **2015**, 16, 494		51
1528	Akkermansia muciniphila and Helicobacter typhlonius modulate intestinal tumor development in mice. **2015**, 36, 1388-96		61
1527	The microbiota and microbiome in aging: potential implications in health and age-related diseases. **2015**, 63, 776-81		163
1526	Microbiome Implications in Intestinal Tumorigenesis. **2015**, 189-209		
1525	Collection media and delayed freezing effects on microbial composition of human stool. **2015**, 3, 33		87
1524	Probiotics Clostridium butyricum and Bacillus subtilis ameliorate intestinal tumorigenesis. **2015**, 10, 1433-45		58
1523	Inflammation-Associated Carcinogenesis Involves Interaction Between the iNOS/NO and Wnt/Ecatenin Signaling Pathways. **2015**, 3-23		
1522	(1)H NMR Spectroscopy of Fecal Extracts Enables Detection of Advanced Colorectal Neoplasia. **2015**, 14, 3871-81		30

1521	Infectious Agents Associated with Head and Neck Carcinomas. **2016**, 897, 63-80	13
1520	Microbiome and cancer. **2015**, 37, 65-72	54
1519	The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. **2015**, 45, 17-31	143
1518	Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers. **2015**, 50, 167-79	156
1517	16. Stellenwert des Mikrobioms in der Genese und Therapie von hÊmatologischen und onkologischen Erkrankungen. **2016**,	
1516	Racial disparity in colorectal cancer: Gut microbiome and cancer stem cells. **2016**, 8, 279-87	4
1515	Historical review of the causes of cancer. **2016**, 7, 54-86	129
1514	Bacteriocin production: a relatively unharnessed probiotic trait?. **2016**, 5, 2587	71
1513	Triterpenoid herbal saponins enhance beneficial bacteria, decrease sulfate-reducing bacteria, modulate inflammatory intestinal microenvironment and exert cancer preventive effects in ApcMin/+ mice. **2016**, 7, 31226-42	38
1512	Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients. **2016**, 22, 3227-33	108
1511	Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. **2016**, 22, 557-66	179
1510	Gut microbiota imbalance and colorectal cancer. **2016**, 22, 501-18	406
1509	Oral Bacteria and Bowel Diseases Mini Review. **2016**, 06,	3
1508	Gut Microbiota Imbalance and Base Excision Repair Dynamics in Colon Cancer. **2016**, 7, 1421-30	23
1507	Tissue-Associated Bacterial Alterations in Rectal Carcinoma Patients Revealed by 16S rRNA Community Profiling. **2016**, 6, 179	76
1506	Metabiotics: One Step ahead of Probiotics; an Insight into Mechanisms Involved in Anticancerous Effect in Colorectal Cancer. **2016**, 7, 1940	68
1505	Current Hypothesis for the Relationship between Dietary Rice Bran Intake, the Intestinal Microbiota and Colorectal Cancer Prevention. **2016**, 8,	17
1504	Cervical Microbiome and Cytokine Profile at Various Stages of Cervical Cancer: A Pilot Study. **2016**, 11, e0153274	151

1503	Bacterially-Associated Transcriptional Remodelling in a Distinct Genomic Subtype of Colorectal Cancer Provides a Plausible Molecular Basis for Disease Development. **2016**, 11, e0166282	27
1502	Host-Microbiome Interaction and Cancer: Potential Application in Precision Medicine. **2016**, 7, 606	24
1501	. **2016**,	8
1500	Metagenome-wide association studies: fine-mining the microbiome. **2016**, 14, 508-22	244
1499	Invasive Fusobacterium nucleatum may play a role in the carcinogenesis of proximal colon cancer through the serrated neoplasia pathway. **2016**, 139, 1318-26	88
1498	Biomarker development in the precision medicine era: lung cancer as a case study. **2016**, 16, 525-37	288
1497	Food storage in a changing world: implications of climate change for food-caching species. **2016**, 3,	20
1496	Linkages between oral commensal bacteria and atherosclerotic plaques in coronary artery disease patients. **2016**, 2, 7	61
1495	Emerging role of bacteria in oral carcinogenesis: a review with special reference to perio-pathogenic bacteria. **2016**, 8, 32762	102
1494	The Gastrointestinal Microbiome. **2016**, 126-137	0
1493	Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease. **2016**, 8, 75	147
1492	UEG Week 2016 Poster Presentations. **2016**, 4, A157-A720	12
1491	Human colorectal mucosal microbiota correlates with its host niche physiology revealed by endomicroscopy. **2016**, 6, 21952	17
1490	Comparison of human gut microbiota in control subjects and patients with colorectal carcinoma in adenoma: Terminal restriction fragment length polymorphism and next-generation sequencing analyses. **2016**, 35, 325-33	78
1489	Oral health and risk of colorectal cancer: results from three cohort studies and a meta-analysis. **2016**, 27, 1329-36	29
1488	[Association between oral conditions and colorectal cancer: A literature review and synthesis]. **2016**, 64, 113-9	4
1487	Gastrointestinal Microbiota and Colon Cancer. **2016**, 34, 244-50	48
1486	Epithelial calcineurin controls microbiota-dependent intestinal tumor development. **2016**, 22, 506-15	68

1485	Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated Cholangiocarcinoma. **2016**, 8, 195-202		61
1484	Gut microbiota: an Indicator to Gastrointestinal Tract Diseases. **2016**, 47, 232-8		14
1483	Benefits of short-chain fatty acids and their receptors in inflammation and carcinogenesis. **2016**, 164, 144-51		219
1482	Agaro-oligosaccharides: a new frontier in the fight against colon cancer?. **2016**, 310, G335-6		15
1481	Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. **2016**, 22, 679-84		445
1480	Mismatch Repair and Colon Cancer: Mechanisms and Therapies Explored. **2016**, 22, 274-289		92
1479	Neue Erkenntnisse zur Rolle der Mikrobiota im kolorektalen Karzinom. **2016**, 54, 406-408		
1478	Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden. **2016**, 9, 721-31		25
1477	Elucidating the gut microbiome of ulcerative colitis: bifidobacteria as novel microbial biomarkers. **2016**, 92,		75
1476	Microbiota-myeloid cell crosstalk beyond the gut. **2016**, 100, 865-879		45
1475	Gut Microbiota, Inflammation, and Colorectal Cancer. **2016**, 70, 395-411		306
1474	Epigenetics, Energy Balance, and Cancer. **2016**,		2
1473	Epigenetic Effects of Gut Microbiota on Obesity and Gastrointestinal Cancers. **2016**, 167-189		1
1472	Colorectal cancer and the microbiota. **2016**, 391-408		
1471	Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc. *Cell Host and Microbe*, **2016**, 20, 215-25	23.4	301
1470	When Mr. Fap Meets the Gals. *Cell Host and Microbe*, **2016**, 20, 125-6	23.4	0
1469	Fusobacterium nucleatum Osteomyelitis of the Femur in a Patient with Hereditary Hemorrhagic Telangiectasia: A Case Report. **2016**, 6, e11		2
1468	How Bacteria are Affected by Toxic Metal Release. **2016**, 253-270		1

1467	Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor. **2016**, 22, 4158-69	22
1466	Extending colonic mucosal microbiome analysis-assessment of colonic lavage as a proxy for endoscopic colonic biopsies. **2016**, 4, 61	35
1465	Diet, microorganisms and their metabolites, and colon cancer. **2016**, 13, 691-706	478
1464	Characterization of the microbiome of nipple aspirate fluid of breast cancer survivors. **2016**, 6, 28061	103
1463	Tea polyphenols inhibit the activation of NF-B and the secretion of cytokines and matrix metalloproteinases by macrophages stimulated with Fusobacterium nucleatum. **2016**, 6, 34520	29
1462	Human Microbiome Fusobacterium Nucleatum in Esophageal Cancer Tissue Is Associated with Prognosis. **2016**, 22, 5574-5581	186
1461	Natural history of the infant gut microbiome and impact of antibiotic treatment on bacterial strain diversity and stability. **2016**, 8, 343ra81	514
1460	Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location. **2016**, 7, e200	156
1459	Role of the Microbiota in Colorectal Cancer: Updates on Microbial Associations and Therapeutic Implications. **2016**, 5, 279-288	36
1458	The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next?. **2016**, 4, 58	170
1457	[How some commensal bacteria would exacerbate colorectal carcinogenesis?]. **2016**, 32, 175-82	4
1456	Oral environment and cancer. **2016**, 38, 13	24
1455	The intestinal microbiome and surgical disease. **2016**, 53, 257-93	16
1454	Target identification in Fusobacterium nucleatum by subtractive genomics approach and enrichment analysis of host-pathogen protein-protein interactions. **2016**, 16, 84	34
1453	Microbial diversity in lake–river ecotone of Poyang Lake, China. **2016**, 75, 1	18
1452	Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. **2016**, 8, 37	169
1451	Manipulation of the Gut Microbiota Reveals Role in Colon Tumorigenesis. **2016**, 1,	70
1450	Metabolic and Community Synergy of Oral Bacteria in Colorectal Cancer. **2016**, 1,	91

1449	An essential role of Ffar2 (Gpr43) in dietary fibre-mediated promotion of healthy composition of gut microbiota and suppression of intestinal carcinogenesis. **2016**, 5, e238	77
1448	Know your neighbor: Microbiota and host epithelial cells interact locally to control intestinal function and physiology. **2016**, 38, 455-64	46
1447	Oncodynamics: Effects of Cancer Cells on the Body. **2016**,	
1446	Fusobacterium nucleatum infections: clinical spectrum and bacteriological features of 78 cases. **2016**, 44, 475-81	17
1445	The Outlook for Immune Checkpoint Targeting Strategies in Colorectal Cancer. **2016**, 12, 51-56	
1444	Clinical applications of bacterial glycoproteins. **2016**, 13, 345-53	8
1443	Taurocholic acid metabolism by gut microbes and colon cancer. **2016**, 7, 201-15	132
1442	Targeting colorectal cancer-associated bacteria: A new area of research for personalized treatments. **2016**, 7, 329-333	14
1441	Probiotics, prebiotics and colorectal cancer prevention. **2016**, 30, 119-31	125
1440	The interplay between the microbiome and the adaptive immune response in cancer development. **2016**, 9, 594-605	39
1439	Does the intestinal microbial community of Korean Crohn's disease patients differ from that of western patients?. **2016**, 16, 28	25
1438	The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. **2016**, 14, 273-87	382
1437	Fusobacterium nucleatum, inflammation, and immunity: the fire within human gut. **2016**, 37, 2805-10	66
1436	Periodontal Pathogens and Risk of Incident Cancer in Postmenopausal Females: The Buffalo OsteoPerio Study. **2016**, 87, 257-67	26
1435	Bacterial protein toxins in human cancers. **2016**, 74, ftv105	25
1434	Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. **2016**, 65, 1973-1980	454
1433	Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. **2017**, 66, 70-78	488
1432	Does the Prevalence of Periodontal Pathogens Change in Elderly Edentulous Patients after Complete Denture Treatment?. **2017**, 26, 364-369	8

1431	The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced murine colon tumorigenesis. **2017**, 10, 421-433	96
1430	Highly sensitive stool DNA testing of Fusobacterium nucleatum as a marker for detection of colorectal tumours in a Japanese population. **2017**, 54, 86-91	46
1429	The Human Microbiome and Cancer. **2017**, 10, 226-234	145
1428	Gut microbiota and colorectal cancer. **2017**, 36, 757-769	106
1427	A non-endoscopic device to sample the oesophageal microbiota: a case-control study. **2017**, 2, 32-42	72
1426	Microbes and Cancer. **2017**, 35, 199-228	127
1425	The structure of the LPS O-chain of Fusobacterium nucleatum strain 25586 containing two novel monosaccharides, 2-acetamido-2,6-dideoxy-l-altrose and a 5-acetimidoylamino-3,5,9-trideoxy-gluco-non-2-ulosonic acid. **2017**, 440-441, 10-15	19
1424	Peptostreptococcus anaerobius Induces Intracellular Cholesterol Biosynthesis in Colon Cells to Induce Proliferation and Causes Dysplasia in Mice. **2017**, 152, 1419-1433.e5	172
1423	Structure of the LPS O-chain from Fusobacterium nucleatum strain 10953, containing sialic acid. **2017**, 440-441, 38-42	16
1422	Tumor Potentiating Mechanisms of Fusobacterium nucleatum, A´Multifaceted Microbe. **2017**, 152, 694-696	16
1421	Mining the Human Gut Microbiota for Immunomodulatory Organisms. **2017**, 168, 928-943.e11	356
1420	Carcinogenesis mechanisms of Fusobacterium nucleatum. **2017**, 89, 918-925	81
1419	Metabolic-Activity-Based Assessment of Antimicrobial Effects by DO-Labeled Single-Cell Raman Microspectroscopy. **2017**, 89, 4108-4115	87
1418	Race-dependent association of sulfidogenic bacteria with colorectal cancer. **2017**, 66, 1983-1994	107
1417	Quantitation of faecal improves faecal immunochemical test in detecting advanced colorectal neoplasia. **2017**, 66, 1441-1448	143
1416	Tumour-associated and non-tumour-associated microbiota in colorectal cancer. **2017**, 66, 633-643	351
1415	Microbiomic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas. **2017**, 9, 14	64
1414	Insights into the role of the intestinal microbiota in colon cancer. **2017**, 10, 417-428	21

1413	Inflammatory disease caused by intestinal pathobionts. **2017**, 35, 64-69	42
1412	Environmental influences in the etiology of colorectal cancer: the premise of metabolomics. **2017**, 3, 114-125	23
1411	Locoregional Effects of Microbiota in a Preclinical Model of Colon Carcinogenesis. **2017**, 77, 2620-2632	140
1410	Subspecies Influences Proinflammatory Cytokine Expression and Monocyte Activation in Human Colorectal Tumors. **2017**, 10, 398-409	74
1409	Periodontal Disease, Tooth Loss, and Cancer Risk. **2017**, 39, 49-58	148
1408	Microbiome and colorectal cancer: Unraveling host-microbiota interactions in colitis-associated colorectal cancer development. **2017**, 32, 3-13	81
1407	The Human Microbiome. **2017**, 63-77	3
1406	Fusobacterium and colorectal cancer: causal factor or passenger? Results from a large colorectal cancer screening study. **2017**, 38, 781-788	74
1405	Human Microbiome: Implications on Health and Disease. **2017**, 153-168	1
1404	Disturbances of the Perioperative Microbiome Across Multiple Body Sites in Patients Undergoing Pancreaticoduodenectomy. **2017**, 46, 260-267	33
1403	Inflammatory bacteriome featuring Fusobacterium nucleatum and Pseudomonas aeruginosa identified in association with oral squamous cell carcinoma. **2017**, 7, 1834	104
1402	Genome Analysis and Human Health. **2017**,	
1401	Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma. **2017**, 471, 329-336	49
1400	The microbiome and hepatobiliary-pancreatic cancers. **2017**, 402, 9-15	70
1399	Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. **2017**, 17, 559-572	865
1398	Mucosa-associated microbiota signature in colorectal cancer. **2017**, 36, 2073-2083	62
1397	Precancer Atlas to Drive Precision Prevention Trials. **2017**, 77, 1510-1541	81
1396	Immunotherapy for colorectal cancer: where are we heading?. **2017**, 17, 709-721	71

1395	The Microbiological Landscape of Anaerobic Infections in Hidradenitis Suppurativa: A Prospective Metagenomic Study. **2017**, 65, 282-291	76
1394	The Composition of Colonic Commensal Bacteria According to Anatomical Localization in Colorectal Cancer. **2017**, 3, 90-97	19
1393	The Human Microbiota in Health and Disease. **2017**, 3, 71-82	351
1392	Microbiota: a key orchestrator of cancer therapy. **2017**, 17, 271-285	455
1391	Drug Targeting of the Human Microbiome. **2017**, 191-214	
1390	Emerging Concepts and Technologies for the Discovery of Microorganisms Involved in Human Disease. **2017**, 12, 217-244	8
1389	Collateral damage: insights into bacterial mechanisms that predispose host cells to cancer. **2017**, 15, 109-128	99
1388	Bacterial Biofilms in Colorectal Cancer Initiation and Progression. **2017**, 23, 18-30	76
1387	Less Invasive Screening for Colorectal Cancer by Microbiota Analysis: Is it a Reality or an Illusion?. **2017**, 25, 5-6	
1386	Microbiome, inflammation and colorectal cancer. **2017**, 32, 43-53	134
1385	Functional Changes in the Gut Microbiome Contribute to Transforming Growth Factor Deficient Colon Cancer. **2017**, 2,	30
1384	Hollow MnO as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses. **2017**, 8, 902	781
1383	A chemical and biological toolbox for Type Vd secretion: Characterization of the phospholipase A1 autotransporter FplA from. **2017**, 292, 20240-20254	18
1382	Fecal Clostridium symbiosum for Noninvasive Detection of Early and Advanced Colorectal Cancer: Test and Validation Studies. **2017**, 25, 32-40	61
1381	A Blueprint to Advance Colorectal Cancer Immunotherapies. **2017**, 5, 942-949	40
1380	Microbiota in digestive cancers: our new partner?. **2017**, 38, 1157-1166	9
1379	Bacterial Infection and Associated Cancers. **2017**, 1018, 181-191	9
1378	Dysbiosis signature of mycobiota in colon polyp and colorectal cancer. **2017**, 36, 2457-2468	44

1377	Cancer-associated fecal microbial markers in colorectal cancer detection. **2017**, 141, 2528-2536	89
1376	Microbiota dysbiosis in select human cancers: Evidence of association and causality. **2017**, 32, 25-34	92
1375	Gavage of Fecal Samples From Patients With Colorectal Cancer Promotes Intestinal Carcinogenesis in Germ-Free and Conventional Mice. **2017**, 153, 1621-1633.e6	274
1374	The colorectal cancer immune microenvironment and approach to immunotherapies. **2017**, 13, 1633-1647	49
1373	Luminally expressed gastrointestinal biomarkers. **2017**, 11, 1119-1134	10
1372	Deciphering interactions between the gut microbiota and the immune system via microbial cultivation and minimal microbiomes. **2017**, 279, 8-22	57
1371	Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention. **2017**, 4, e000145	180
1370	Immunization with alkyl hydroperoxide reductase subunit C reduces Fusobacterium nucleatum load in the intestinal tract. **2017**, 7, 10566	9
1369	Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer. **2017**, 7, 11590	101
1368	Tumour-targeting bacteria-based cancer therapies for increased specificity and improved outcome. **2017**, 10, 1074-1078	23
1367	Regulation of Inflammatory Signaling in Health and Disease. **2017**,	4
1366	Microbial Factors in Inflammatory Diseases and Cancers. **2017**, 1024, 153-174	14
1365	Diet, microbiome, and colorectal cancer. **2017**, 31, 675-681	3
1364	Microbial Communities Associated with Primary and Metastatic Head and Neck Squamous Cell Carcinoma - A High Fusobacterial and Low Streptococcal Signature. **2017**, 7, 9934	42
1363	A prospective analysis of mucosal microbiome-metabonome interactions in colorectal cancer using a combined MAS 1HNMR and metataxonomic strategy. **2017**, 7, 8979	25
1362	No patient left behind: The promise of immune priming with epigenetic agents. **2017**, 6, e1315486	10
1361	Regulation of inflammation by microbiota interactions with the host. **2017**, 18, 851-860	318
1360	The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms. **2017**, 26, 368-376	41

1359	The microbiota revolution: Excitement and caution. **2017**, 47, 1406-1413		16
1358	Drugs, Bugs, and Cancer: Fusobacterium nucleatum Promotes Chemoresistance in Colorectal Cancer. **2017**, 170, 411-413		36
1357	Alterations of microbiota structure in the larynx relevant to laryngeal carcinoma. **2017**, 7, 5507		20
1356	Periodontal Disease and Incident Cancer Risk among Postmenopausal Women: Results from the Women's Health Initiative Observational Cohort. **2017**, 26, 1255-1265		53
1355	Analysis of persistence and antibiotic response in colorectal cancer. **2017**, 358, 1443-1448		578
1354	High-resolution bacterial 16S rRNA gene profile meta-analysis and biofilm status reveal common colorectal cancer consortia. **2017**, 3, 34		145
1353	Infectious Agents Associated Cancers: Epidemiology and Molecular Biology. **2017**,		1
1352	Diet, Gut Microbiota, and Colorectal Cancer Prevention: A Review of Potential Mechanisms and Promising Targets for Future Research. **2017**, 13, 429-439		25
1351	Rare Biosphere in Human Gut: A Less Explored Component of Human Gut Microbiota and Its Association with Human Health. **2017**, 133-142		3
1350	Omics-based biomarkers: current status and potential use in the clinic. **2017**, 74, 219-226		24
1349	The influence of the commensal microbiota on distal tumor-promoting inflammation. **2017**, 32, 62-73		17
1348	Increased cancer risk in patients with periodontitis. **2017**, 33, 2195-2200		27
1347	Indoleacrylic Acid Produced by Commensal Peptostreptococcus Species Suppresses Inflammation. *Cell Host and Microbe*, **2017**, 22, 25-37.e6	23.4	287
1346	Distinguishing potential bacteria-tumor associations from contamination in a secondary data analysis of public cancer genome sequence data. **2017**, 5, 9		34
1345	Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-Ƀ, and Up-regulating Expression of MicroRNA-21. **2017**, 152, 851-866.e24		380
1344	Periodontal disease, tooth loss and colorectal cancer risk: Results from the Nurses' Health Study. **2017**, 140, 646-652		65
1343	Microbiome-driven carcinogenesis in colorectal cancer: Models and mechanisms. **2017**, 105, 3-15		56
1342	Microbiota as a mediator of cancer progression and therapy. **2017**, 179, 139-154		41

1341	Fecal Bacteria Act as Novel Biomarkers for Noninvasive Diagnosis of Colorectal Cancer. **2017**, 23, 2061-2070	161
1340	Stool- and Blood-Based Molecular Tests in Screening for Colorectal Cancer: Ready for Prime Time?. **2017**, 13, 481-488	
1339	Omics-based biomarkers: current status and potential use in the clinic. **2017**, 74, 219-226	7
1338	HIV-associated changes in the enteric microbial community: potential role in loss of homeostasis and development of systemic inflammation. **2017**, 30, 31-43	52
1337	Evolutionary biologic changes of gut microbiota in an 'adenoma-carcinoma sequence' mouse colorectal cancer model induced by 1, 2-Dimethylhydrazine. **2017**, 8, 444-457	30
1336	Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. **2017**, 18,	496
1335	Microbiota, Inflammation and Colorectal Cancer. **2017**, 18,	128
1334	Tumor Targeting by : A Pilot Study and Future Perspectives. **2017**, 7, 295	31
1333	Linking Gut Microbiota to Colorectal Cancer. **2017**, 8, 3378-3395	76
1332	TLR2/TLR4 activation induces Tregs and suppresses intestinal inflammation caused by Fusobacterium nucleatum in vivo. **2017**, 12, e0186179	27
1331	The microbiome and the hallmarks of cancer. **2017**, 13, e1006480	68
1330	Perturbed human sub-networks by Fusobacterium nucleatum candidate virulence proteins. **2017**, 5, 89	19
1329	Normalization of the microbiota in patients after treatment for colonic lesions. **2017**, 5, 150	37
1328	Cancer and Aging - the Inflammatory Connection. **2017**, 8, 611-627	67
1327	's link to colorectal neoplasia sequenced: A systematic review and future insights. **2017**, 23, 8626-8650	38
1326	High-resolution microbiome profiling uncovers , , and associated to oral and oropharyngeal cancer in saliva from HPV positive and HPV negative patients treated with surgery and chemo-radiation. **2017**, 8, 110931-110948	47
1325	Focus on periodontal disease and colorectal carcinoma. **2017**, 10, 229-233	13
1324	The role of bacterial culture by bronchoscopy in patients with lung cancer: a prospective study. **2017**, 9, 5300-5305	2

1323	Human Gut Microbiota and Gastrointestinal Cancer. **2018**, 16, 33-49	137
1322	Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis in Mice via a Toll-Like Receptor 4/p21-Activated Kinase 1 Cascade. **2018**, 63, 1210-1218	51
1321	Dysbiosis of gut microbiota in promoting the development of colorectal cancer. **2018**, 6, 1-12	110
1320	Tumor-associated myeloid cells: new understandings on their metabolic regulation and their influence in cancer immunotherapy. **2018**, 285, 717-733	34
1319	Does the microbiome and virome contribute to myalgic encephalomyelitis/chronic fatigue syndrome?. **2018**, 132, 523-542	25
1318	Indoleamine 2,3-dioxygenase expression regulates the survival and proliferation of Fusobacterium nucleatum in THP-1-derived macrophages. **2018**, 9, 355	31
1317	Gut microbiome of Moroccan colorectal cancer patients. **2018**, 207, 211-225	35
1316	Forward Genetic Dissection of Biofilm Development by Fusobacterium nucleatum: Novel Functions of Cell Division Proteins FtsX and EnvC. **2018**, 9,	21
1315	Exploring the microbiota to better understand gastrointestinal cancers physiology. **2018**, 56, 1400-1412	20
1314	The Role of the Gut Microbiome in Colorectal Cancer. **2018**, 31, 192-198	26
1313	Structural Modification of Natural Product Ganomycin I Leading to Discovery of a □Glucosidase and HMG-CoA Reductase Dual Inhibitor Improving Obesity and Metabolic Dysfunction in Vivo. **2018**, 61, 3609-3625	33
1312	Current understanding of the human microbiome. **2018**, 24, 392-400	823
1311	The New Frontier: the Intestinal Microbiome and Surgery. **2018**, 22, 1277-1285	6
1310	The Intestinal Microbiota in Colorectal Cancer. **2018**, 33, 954-964	314
1309	Spatial Variation of the Native Colon Microbiota in Healthy Adults. **2018**, 11, 393-402	33
1308	Microbial metabolites, short-chain fatty acids, restrain tissue bacterial load, chronic inflammation, and associated cancer in the colon of mice. **2018**, 48, 1235-1247	40
1307	Crosstalk between gut microbiota and Sirtuin-3 in colonic inflammation and tumorigenesis. **2018**, 50, 1-11	28
1306	Metaorganisms in extreme environments: do microbes play a role in organismal adaptation?. **2018**, 127, 1-19	94

1305	Risk of colorectal cancer in patients with periodontal disease severity: a nationwide, population-based cohort study. **2018**, 33, 349-352	15
1304	An Update on Colorectal Cancer. **2018**, 55, 76-116	14
1303	The microbiome and cancer. **2018**, 244, 667-676	98
1302	Fecal Microbiota Transplants: Current Knowledge and Future Directions. **2018**, 279-302	
1301	Colorectal cancer: Hand-in-hand - colorectal cancer metastasizes with microorganisms. **2018**, 15, 133-134	4
1300	Gut microbiome influences on anastomotic leak and recurrence rates following colorectal cancer surgery. **2018**, 105, e131-e141	73
1299	Periodontal Disease Assessed Using Clinical Dental Measurements and Cancer Risk in the ARIC Study. **2018**, 110, 843-854	60
1298	Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. **2018**, 67, 1168-1180	111
1297	Variations among Streptococcus gallolyticus subsp. gallolyticus strains in connection with colorectal cancer. **2018**, 8, 1514	18
1296	Understanding the microbiome: Emerging biomarkers for exploiting the microbiota for personalized medicine against cancer. **2018**, 52, 1-8	58
1295	Emerging Insights into the Esophageal Microbiome. **2018**, 16, 72-85	35
1294	The regulation of host cellular and gut microbial metabolism in the development and prevention of colorectal cancer. **2018**, 44, 436-454	12
1293	[Gut microbiota: What impact on colorectal carcinogenesis and treatment?]. **2018**, 105, 70-80	10
1292	Is metformin poised for a second career as an antimicrobial?. **2018**, 34, e2975	48
1291	Molecular mechanistic pathway of colorectal carcinogenesis associated with intestinal microbiota. **2018**, 49, 63-70	19
1290	Oral-gut connection: one step closer to an integrated view of the gastrointestinal tract?. **2018**, 11, 316-318	28
1289	Association Between Bacteremia From Specific Microbes and Subsequent Diagnosis of Colorectal Cancer. **2018**, 155, 383-390.e8	105
1288	The association of diet, gut microbiota and colorectal cancer: what we eat may imply what we get. **2018**, 9, 474-487	113

1287	Induction and modulation of genotoxicity by the bacteriome in mammals. **2018**, 776, 70-77	8
1286	Parabacteroides distasonis attenuates toll-like receptor 4 signaling and Akt activation and blocks colon tumor formation in high-fat diet-fed azoxymethane-treated mice. **2018**, 143, 1797-1805	41
1285	Diets That Promote Colon Inflammation Associate With Risk of Colorectal Carcinomas That Contain Fusobacterium nucleatum. **2018**, 16, 1622-1631.e3	63
1284	Synthesis of multi-omic data and community metabolic models reveals insights into the role of hydrogen sulfide in colon cancer. **2018**, 149, 59-68	35
1283	Beyond Tissue Stiffness and Bioadhesivity: Advanced Biomaterials to Model Tumor Microenvironments and Drug Resistance. **2018**, 4, 281-291	19
1282	Systematic review: Gut microbiota in fecal samples and detection of colorectal neoplasms. **2018**, 9, 293-307	20
1281	Molecular Analysis of the Microbiome in Colorectal Cancer. **2018**, 1765, 139-153	2
1280	Mikrobielle Biomarker zur Krebsfrüherkennung. **2018**, 39, 55-62	
1279	Microbial Interactions and Interventions in Colorectal Cancer. **2017**, 5,	27
1278	Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects. **2018**, 142, 769-778	85
1277	The oral microbiota in colorectal cancer is distinctive and predictive. **2018**, 67, 1454-1463	233
1276	Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese population. **2018**, 53, 517-524	77
1275	How the microbiome is shaping our understanding of cancer biology and its treatment. **2018**, 29, 12-16	7
1274	Mucosa-associated microbiota dysbiosis in colitis associated cancer. **2018**, 9, 131-142	83
1273	Gut microbiome: a new player in gastrointestinal disease. **2018**, 472, 159-172	47
1272	The Impact of the Gut Microbiome on Colorectal Cancer. **2018**, 2, 229-249	17
1271	and colorectal cancer: A review. **2018**, 10, 71-81	125
1270	SERUM CYTOKINE OF IL-2, IL-10 AND IL-12 LEVELS IN PATIENTS WITH STOMACH ADENOCARCINOMA. **2018**, 55, 385-389	8

1269	Microbiota and Colon Cancer: Orchestrating Neoplasia Through DNA Damage and Immune Dysregulation. **2018**, 458-458	
1268	Dysbiosis of the gut microbiota and colorectal cancer: the key target of molecular pathological epidemiology. **2018**, 3,	24
1267	Deciphering the immune microenvironment of a tissue by digital imaging and cognition network. **2018**, 8, 16692	5
1266	Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis. **2018**, 25, 79	134
1265	Streptococcus gallolyticus conspires myeloid cells to promote tumorigenesis of inflammatory bowel disease. **2018**, 506, 907-911	19
1264	Gut microbiome profiling and colorectal cancer in African Americans and Caucasian Americans. **2018**, 9, 47-58	25
1263	Relationship between , inflammatory mediators and microRNAs in colorectal carcinogenesis. **2018**, 24, 5351-5365	45
1262	Characterisation of gut, lung, and upper airways microbiota in patients with non-small cell lung carcinoma: Study protocol for case-control observational trial. **2018**, 97, e13676	16
1261	Barrett's esophagus and esophageal cancer: Links to microbes and the microbiome. **2018**, 14, e1007384	14
1260	Gut Microbiota, Fusobacteria, and Colorectal Cancer. **2018**, 6,	49
1259	Therapeutic faecal microbiota transplantation controls intestinal inflammation through IL10 secretion by immune cells. **2018**, 9, 5184	103
1258	and Colorectal Cancer. **2018**, 8, 371	52
1257	Enrichment of gut-derived Fusobacterium is associated with suboptimal immune recovery in HIV-infected individuals. **2018**, 8, 14277	32
1256	Drug resistance and new therapies in colorectal cancer. **2018**, 24, 3834-3848	220
1255	NLRP6 negatively regulates pulmonary host defense in Gram-positive bacterial infection through modulating neutrophil recruitment and function. **2018**, 14, e1007308	41
1254	Grow With the Challenge - Microbial Effects on Epithelial Proliferation, Carcinogenesis, and Cancer Therapy. **2018**, 9, 2020	16
1253	The Unfolding Story of ATF6, Microbial Dysbiosis, and Colorectal Cancer. **2018**, 155, 1309-1311	7
1252	Microbiota effects on cancer: from risks to therapies. **2018**, 9, 17915-17927	101

1251	Colorectal carcinogenesis: an archetype of gut microbiota-host interaction. **2018**, 12, 865	18
1250	Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers. **2018**, 10, 78	69
1249	Microbiome and Colorectal Cancer. **2018**, 14, 217-225	2
1248	The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy. **2018**, 39, 900-920	36
1247	Mucosal microbiota of intestinal polyps reveals putative biomarkers of colorectal cancer. **2018**, 8, 13974	65
1246	in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status. **2018**, 6, 1327-1336	78
1245	Detection of Colorectal Carcinoma Based on Microbiota Analysis Using Generalized Regression Neural Networks and Nonlinear Feature Selection. **2020**, 17, 547-557	4
1244	The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease. **2018**, 9, 2247	258
1243	The gut microbiome and colorectal cancer: a review of bacterial pathogenesis. **2018**, 9, 769-777	79
1242	Relationship of the mucosal microbiota to gastrointestinal inflammation and small cell intestinal lymphoma in cats. **2018**, 32, 1692-1702	11
1241	Changes in gut microbiota and plasma inflammatory factors across the stages of colorectal tumorigenesis: a case-control study. **2018**, 18, 92	28
1240	Microbial Interactions and Interventions in Colorectal Cancer. **2018**, 99-130	1
1239	Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer. **2018**, 15, 671-682	152
1238	Colorectal cancer prevention in patients with ulcerative colitis. **2018**, 32-33, 103-109	35
1237	TOX expression decreases with progression of colorectal cancers and is associated with CD4 T-cell density and Fusobacterium nucleatum infection. **2018**, 79, 93-101	32
1236	Periodontal disease and susceptibility to breast cancer: A meta-analysis of observational studies. **2018**, 45, 1025-1033	18
1235	Replication Study: infection is prevalent in human colorectal carcinoma. **2018**, 7,	31
1234	The who, where and how of fusobacteria and colon cancer. **2018**, 7,	14

1233	Mechanisms of Gastrointestinal Malignancies. **2018**, 1615-1642	1
1232	Role of intestinal flora in colorectal cancer from the metabolite perspective: a systematic review. **2018**, 10, 199-206	29
1231	Microbiome and Diseases: Colorectal Cancer. **2018**, 231-249	2
1230	FusoPortal: an Interactive Repository of Hybrid MinION-Sequenced Genomes Improves Gene Identification and Characterization. **2018**, 3,	7
1229	Association Between Fusobacterium nucleatum, Pathway Mutation, and Patient Prognosis in Colorectal Cancer. **2018**, 25, 3389-3395	46
1228	Dual functional roles of the MyD88 signaling in colorectal cancer development. **2018**, 107, 177-184	23
1227	Effects of the intestinal microbial metabolite butyrate on the development of colorectal cancer. **2018**, 9, 2510-2517	93
1226	Association between and colorectal cancer: Progress and future directions. **2018**, 9, 1652-1659	40
1225	Preliminary Comparison of Oral and Intestinal Human Microbiota in Patients with Colorectal Cancer: A Pilot Study. **2017**, 8, 2699	63
1224	Gut Microbiota: An Integral Moderator in Health and Disease. **2018**, 9, 151	185
1223	The Pivotal Role of DNA Repair in Infection Mediated-Inflammation and Cancer. **2018**, 9, 663	19
1222	16S rRNA Gene Sequencing for Deciphering the Colorectal Cancer Gut Microbiome: Current Protocols and Workflows. **2018**, 9, 767	23
1221	Oral Bacterial and Fungal Microbiome Impacts Colorectal Carcinogenesis. **2018**, 9, 774	40
1220	Metformin Alters Gut Microbiota of Healthy Mice: Implication for Its Potential Role in Gut Microbiota Homeostasis. **2018**, 9, 1336	35
1219	CoreProbe: A Novel Algorithm for Estimating Relative Abundance Based on Metagenomic Reads. **2018**, 9,	0
1218	Severe Defects in the Macrophage Barrier to Gut Microflora in Inflammatory Bowel Disease and Colon Cancer. **2018**, 38, 3811-3815	17
1217	Genomics Using MinION and Illumina Sequencing Enables Genome Completion and Correction. **2018**, 3,	15
1216	Role of Microbiota and Tryptophan Metabolites in the Remote Effect of Intestinal Inflammation on Brain and Depression. **2018**, 11,	75

1215	Fecal Microbiota and Screening for Colorectal Cancer. **2018**, 64, 1273-1274	3
1214	Stool Microbiota Composition Differs in Patients with Stomach, Colon, and Rectal Neoplasms. **2018**, 63, 2950-2958	37
1213	Intestinal Stem Cells and Their Defining Niche. **2018**, 2, 1-40	2
1212	Microbial markers in colorectal cancer detection and/or prognosis. **2018**, 24, 2327-2347	53
1211	promotes the progression of colorectal cancer by interacting with E-cadherin. **2018**, 16, 2606-2612	25
1210	Diagnostic Performance of Intestinal in Colorectal Cancer: A Meta-Analysis. **2018**, 131, 1349-1356	13
1209	T Cells: Crosstalk Between Microbiota, Chronic Inflammation, and Colorectal Cancer. **2018**, 9, 1483	25
1208	Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. **2018**, 6, 70	165
1207	Investigations on the interplays between Schistosoma mansoni, praziquantel and the gut microbiome. **2018**, 11, 168	34
1206	Infection in Colorectal Cancer: Linking Inflammation, DNA Mismatch Repair and Genetic and Epigenetic Alterations. **2018**, 2, 37-46	26
1205	Fusobacterium nucleatum promotes M2 polarization of macrophages in the microenvironment of colorectal tumours via a TLR4-dependent mechanism. **2018**, 67, 1635-1646	64
1204	Intestinal microbiota, chronic inflammation, and colorectal cancer. **2018**, 16, 338-345	54
1203	A critical review on the impacts of glucans on gut microbiota and human health. **2018**, 61, 101-110	119
1202	Impact of microbiota in colorectal carcinogenesis: lessons from experimental models. **2018**, 16, 346-357	30
1201	Oral infection of mice with Fusobacterium nucleatum results in macrophage recruitment to the dental pulp and bone resorption. **2018**, 41, 184-193	11
1200	Overexpression of miR-21-5p promotes proliferation and invasion of colon adenocarcinoma cells through targeting CHL1. **2018**, 24, 36	28
1199	Interaction between the microbiome and TP53 in human lung cancer. **2018**, 19, 123	118
1198	The urinary microbiome associated with bladder cancer. **2018**, 8, 12157	88

1197	Phylogeny-corrected identification of microbial gene families relevant to human gut colonization. **2018**, 14, e1006242	16
1196	Leveraging Existing 16S rRNA Gene Surveys To Identify Reproducible Biomarkers in Individuals with Colorectal Tumors. **2018**, 9,	30
1195	The Canonical Wnt Pathway Drives Macropinocytosis in Cancer. **2018**, 78, 4658-4670	48
1194	Associations Between Race, Perceived Psychological Stress, and the Gut Microbiota in a Sample of Generally Healthy Black and White Women: A Pilot Study on the Role of Race and Perceived Psychological Stress. **2018**, 80, 640-648	20
1193	Microbiome and butyrate production are altered in the gut of rats fed a glycated fish protein diet. **2018**, 47, 423-433	34
1192	Prebiotics and Probiotics in Altering Microbiota: Implications in Colorectal Cancer. **2018**, 403-413	2
1191	Intestinal-Based Diseases and Peripheral Infection Risk Associated with Gut Dysbiosis: Therapeutic use of Pre- and Probiotics and Fecal Microbiota Transplantation. **2018**, 197-288	
1190	Clinical applications of gut microbiota in cancer biology. **2019**, 55, 28-36	52
1189	Human antimicrobial peptides and cancer. **2019**, 88, 156-162	34
1188	Patients with colorectal cancer have identical strains of in their colorectal cancer and oral cavity. **2019**, 68, 1335-1337	105
1187	2-Methacryloyloxyethyl phosphorylcholine (MPC)-polymer suppresses an increase of oral bacteria: a single-blind, crossover clinical trial. **2019**, 23, 739-746	14
1186	Insights into Pathogenic Interactions Among Environment, Host, and Tumor at the Crossroads of Molecular Pathology and Epidemiology. **2019**, 14, 83-103	117
1185	Controversy on the correlation of red and processed meat consumption with colorectal cancer risk: an Asian perspective. **2019**, 59, 3526-3537	7
1184	Mikrobiota und Genese des kolorektalen Karzinoms. **2019**, 52, 30-34	
1183	Intratumoral Levels Predict Therapeutic Response to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma. **2019**, 25, 6170-6179	43
1182	Microbiome and Melanoma. **2019**, 287-302	
1181	Aberrantly hypermethylated tumor suppressor genes were identified in oral squamous cell carcinoma (OSCC). **2019**, 11, 116	24
1180	Microbiota Profile and Impact of in Colorectal Cancer Patients of Barretos Cancer Hospital. **2019**, 9, 813	23

1179	The influence of the microbiota on immune development, chronic inflammation, and cancer in the context of aging. **2019**, 6, 324-334	26
1178	Fusobacterium nucleatum tumor DNA levels are associated with survival in colorectal cancer patients. **2019**, 38, 1891-1899	22
1177	Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy. **2019**, 3, 717-728	101
1176	Editing of the gut microbiota reduces carcinogenesis in mouse models of colitis-associated colorectal cancer. **2019**, 216, 2378-2393	50
1175	Analysis of and in saliva of colorectal cancer patients. **2019**, 13, 725-735	12
1174	Reactive Oxygen Species in the Tumor Microenvironment: An Overview. **2019**, 11,	156
1173	Interplay of Liver Disease and Gut Microbiota in the Development of Colorectal Neoplasia. **2019**, 17, 378-393	4
1172	-positive colorectal cancer. **2019**, 18, 975-982	16
1171	Inflammation and Cancer: Triggers, Mechanisms, and Consequences. **2019**, 51, 27-41	746
1170	Oral microbiota and gastrointestinal cancer. **2019**, 12, 4721-4728	13
1169	Induction of CD8 T cell cytotoxicity by fecal bacteria from healthy individuals and colorectal cancer patients. **2019**, 516, 1007-1012	2
1168	Global Investigations of in Human Colorectal Cancer. **2019**, 9, 566	27
1167	Colorectal cancer, radiotherapy and gut microbiota. **2019**, 31, 212-222	11
1166	Genomics and metagenomics of colorectal cancer. **2019**, 10, 1164-1170	17
1165	Lifestyle and dietary environmental factors in colorectal cancer susceptibility. **2019**, 69, 2-9	69
1164	An updated review of microsatellite instability in the era of next-generation sequencing and precision medicine. **2019**, 46, 261-270	29
1163	The critical role of calcineurin/NFAT (C/N) pathways and effective antitumor prospect for colorectal cancers. **2019**, 120, 19254-19273	7
1162	Potential Mechanisms of Probiotics Action in the Prevention and Treatment of Colorectal Cancer. **2019**, 11,	51

1161	Protective Role of Fecal Microbiota Transplantation on Colitis and Colitis-Associated Colon Cancer in Mice Is Associated With Treg Cells. **2019**, 10, 2498	30
1160	The role of in colorectal cancer: from carcinogenesis to clinical management. **2019**, 5, 178-187	37
1159	Diet, Microbiota, and Colorectal Cancer. **2019**, 21, 168-187	14
1158	Framework for rational donor selection in fecal microbiota transplant clinical trials. **2019**, 14, e0222881	20
1157	The Four Horsemen in Colon Cancer. **2019**, 2019, 5636272	17
1156	Functions and Implications of Autophagy in Colon Cancer. **2019**, 8,	26
1155	Oncolytic Bacteria and their potential role in bacterium-mediated tumour therapy: a conceptual analysis. **2019**, 10, 4442-4454	15
1154	Gut Microbiota Influences Experimental Outcomes in Mouse Models of Colorectal Cancer. **2019**, 10,	21
1153	Intestinal microbiota and colorectal carcinoma: Implications for pathogenesis, diagnosis, and therapy. **2019**, 48, 648-655	30
1152	The Role of the Gut Microbiota in Colorectal Cancer Causation. **2019**, 20,	46
1151	Targeting Programmed Fap2 for Colorectal Cancer Therapy. **2019**, 11,	19
1150	Colorectal cancer. **2019**, 394, 1467-1480	1051
1149	The Cancer Microbiota: EMT and Inflammation as Shared Molecular Mechanisms Associated with Plasticity and Progression. **2019**, 2019, 1253727	30
1148	Role of Dietary Lipids in Modulating Inflammation through the Gut Microbiota. **2019**, 11,	27
1147	Crosstalk between Vaginal Microbiome and Female Health: A review. **2019**, 136, 103696	41
1146	The Clinical Link between Human Intestinal Microbiota and Systemic Cancer Therapy. **2019**, 20,	24
1145	Oral Bacteria and Intestinal Dysbiosis in Colorectal Cancer. **2019**, 20,	63
1144	[Microbial regulation of tumor development and responses to tumor therapy]. **2019**, 57, 883-888	0

1143	A Reasonable Diet Promotes Balance of Intestinal Microbiota: Prevention of Precolorectal Cancer. **2019**, 2019, 3405278	17
1142	Cancer Biomarkers in Body Fluids. **2019**,	1
1141	Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity. **2019**, 4, 2319-2330	120
1140	Time-Course Transcriptome Analysis for Drug Repositioning in -Infected Human Gingival Fibroblasts. **2019**, 7, 204	8
1139	Diminishing microbiome richness and distinction in the lower respiratory tract of lung cancer patients: A multiple comparative study design with independent validation. **2019**, 136, 129-135	25
1138	Utilizing Whole Genomes To Identify, Correct, and Characterize Potential Virulence Protein Families. **2019**, 201,	17
1137	Die intestinale Mikrobiota in der Onkologie. **2019**, 51, 108-112	
1136	Cinobufacini ameliorates experimental colitis via modulating the composition of gut microbiota. **2019**, 14, e0223231	2
1135	Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. **2019**, 16, 690-704	276
1134	Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer. **2019**, 20,	2
1133	The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer. **2019**, 20,	19
1132	Commensal Microbiota Promote Lung Cancer Development via T Cells. **2019**, 176, 998-1013.e16	290
1131	Proteomic characterization of outer membrane vesicles from gut mucosa-derived fusobacterium nucleatum. **2019**, 195, 125-137	21
1130	The Gut Microbiome: Unleashing the Doctor Within. **2019**, 13, 265-268	
1129	Microbiota and gastrointestinal cancer. **2019**, 118 Suppl 1, S32-S41	34
1128	The Gut Microbiome and Food as Medicine: Healthy Microbiomes = Healthy Humans. **2019**, 33, 821-824	2
1127	The Microbiome of Oral Squamous Cell Carcinomas: a Functional Perspective. **2019**, 6, 145-160	32
1126	Microbiome and colorectal cancer: Roles in carcinogenesis and clinical potential. **2019**, 69, 93-106	101

1125	Bacterial biofilms as a potential contributor to mucinous colorectal cancer formation. **2019**, 1872, 74-79	22
1124	Quantitative microbiome profiling disentangles inflammation- and bile duct obstruction-associated microbiota alterations across PSC/IBD diagnoses. **2019**, 4, 1826-1831	71
1123	Exploring the impact of Helicobacter pylori on gut microbiome composition. **2019**, 14, e0218274	47
1122	The microbiome and cancer for clinicians. **2019**, 141, 1-12	50
1121	Impact of Host DNA and Sequencing Depth on the Taxonomic Resolution of Whole Metagenome Sequencing for Microbiome Analysis. **2019**, 10, 1277	63
1120	Towards a Food Pharmacy: Immunologic Modulation through Diet. **2019**, 11,	19
1119	Response to Comment on "Trapping of Lipopolysaccharide to Promote Immunotherapy against Colorectal Cancer and Attenuate Liver Metastasis". **2019**, 31, e1902569	
1118	Aggravates the Progression of Colitis by Regulating M1 Macrophage Polarization via AKT2 Pathway. **2019**, 10, 1324	35
1117	The microbiota and microbiome in pancreatic cancer: more influential than expected. **2019**, 18, 97	88
1116	Dysbiosis Disrupts Gut Immune Homeostasis and Promotes Gastric Diseases. **2019**, 20,	41
1115	On the Immune Status of Patients with Colorectal Carcinoma. **2019**, 147-161	
1114	Moderate alteration to gut microbiota brought by colorectal adenoma resection. **2019**, 34, 1758-1765	3
1113	The presence of bacteria varies between colorectal adenocarcinomas, precursor lesions and non-malignant tissue. **2019**, 19, 399	35
1112	Fusobacterium nucleatum, the communication with colorectal cancer. **2019**, 116, 108988	15
1111	Emergency Surgical Management of Colorectal Cancer. **2019**,	0
1110	Is a fusobacterium nucleatum infection in the colon a risk factor for colorectal cancer?: a systematic review and meta-analysis protocol. **2019**, 8, 114	10
1109	Relationship between intestinal microorganisms and T lymphocytes in colorectal cancer. **2019**, 15, 1655-1666	7
1108	Editor's Desk: Masterful Microbes: The Gut Microbiome and Food as Medicine. **2019**, 33, 820-834	1

1107	Gut microbiome associated with chemotherapy-induced diarrhea from the CapeOX regimen as adjuvant chemotherapy in resected stage III colorectal cancer. **2019**, 11, 18	11
1106	International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis. **2019**, 68, 1624-1632	101
1105	Periodontitis is associated with an increased risk for proximal colorectal neoplasms. **2019**, 9, 7528	11
1104	Oral Health and Cancer. **2019**, 6, 130-137	14
1103	supresses anti-tumor immunity by activating CEACAM1. **2019**, 8, e1581531	43
1102	Host?MicroRNA?Microbiota Interactions in Colorectal Cancer. **2019**, 10,	14
1101	Culture-independent studies on bacterial dysbiosis in oral and oropharyngeal squamous cell carcinoma: A systematic review. **2019**, 139, 31-40	14
1100	Gut microbial biofilm composition and organisation holds the key to CRC. **2019**, 16, 329-330	11
1099	Fusobacterium nucleatum Contributes to the Carcinogenesis of Colorectal Cancer by Inducing Inflammation and Suppressing Host Immunity. **2019**, 12, 846-851	77
1098	Impact of the microbiome on cancer progression and response to anti-cancer therapies. **2019**, 143, 255-294	10
1097	Detection of Fusobacterium nucleatum in stool and colonic tissues from Norwegian colorectal cancer patients. **2019**, 38, 1367-1376	18
1096	Reduction of faecal immunochemical test false-positive results using a signature based on faecal bacterial markers. **2019**, 49, 1410-1420	8
1095	Role of SCFAs in gut microbiome and glycolysis for colorectal cancer therapy. **2019**, 234, 17023-17049	60
1094	Microbiome and Melanoma. **2019**, 1-16	
1093	The application of Apc mouse model in colorectal tumor researches. **2019**, 145, 1111-1122	13
1092	The microbiome, cancer, and cancer therapy. **2019**, 25, 377-388	355
1091	Association between periodontal pathogens and systemic disease. **2019**, 42, 27-35	191
1090	promotes colorectal cancer by inducing Wnt/□catenin modulator Annexin A1. **2019**, 20,	133

1089	Importance of probiotics in the prevention and treatment of colorectal cancer. **2019**, 234, 17127-17143	78
1088	Inter-kingdom signaling between gut microbiota and their host. **2019**, 76, 2383-2389	21
1087	Infections and Pancreatic Cancer. **2019**, 125-133	
1086	The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis. **2019**, 10, 139	51
1085	Chronic Inflammation as a Link between Periodontitis and Carcinogenesis. **2019**, 2019, 1029857	58
1084	Current Understanding of the Gut Microflora in Subjects with Nutrition-Associated Metabolic Disorder Such as Obesity and/or Diabetes: Is There Any Relevance with Oral Microflora?. **2019**, 6, 100-109	
1083	Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. **2019**, 25, 667-678	289
1082	Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. **2019**, 25, 679-689	353
1081	The Role of the Microbiome in Immunologic Development and its Implication For Pancreatic Cancer Immunotherapy. **2019**, 156, 2097-2115.e2	48
1080	Gut Microbiome in Health and Disease: Emerging Diagnostic Opportunities. **2019**, 48, 221-235	13
1079	Small RNA expression from viruses, bacteria and human miRNAs in colon cancer tissue and its association with microsatellite instability and tumor location. **2019**, 19, 161	16
1078	Microbiome and Human Malignancies. **2019**, 1-22	
1077	The Dimension of Time in Host-Microbiome Interactions. **2019**, 4,	27
1076	Bugs, drugs, and cancer: can the microbiome be a potential therapeutic target for cancer management?. **2019**, 24, 1000-1009	7
1075	Compositional Analysis of the Human Microbiome in Cancer Research. **2019**, 1928, 299-335	1
1074	Epigenetic silencing of the synthesis of immunosuppressive Siglec ligand glycans by NF-Ƀ/EZH2/YY1 axis in early-stage colon cancers. **2019**, 1862, 173-183	11
1073	The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients. **2019**, 9, 1691	33
1072	The Presence of Gut Microbial Genes Encoding Bacterial Genotoxins or Pro-Inflammatory Factors in Stool Samples from Individuals with Colorectal Neoplasia. **2019**, 7,	2

1071	The Developing Story of Predictive Biomarkers in Colorectal Cancer. **2019**, 9,		65
1070	Emerging applications of upconverting nanoparticles in intestinal infection and colorectal cancer. **2019**, 14, 1027-1038		32
1069	Impact of the gut microbiome on the genome and epigenome of colon epithelial cells: contributions to colorectal cancer development. **2019**, 11, 11		79
1068	The Use of Probiotic Therapy to Modulate the Gut Microbiota and Dendritic Cell Responses in Inflammatory Bowel Diseases. **2019**, 7,		6
1067	Innate Immune Pattern Recognition and the Development of Intestinal Cancer. **2019**, 299-316		2
1066	Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis. **2019**, 156, 1440-1454.e2		169
1065	Neutrophils Restrict Tumor-Associated Microbiota to Reduce Growth and Invasion of Colon Tumors in Mice. **2019**, 156, 1467-1482		37
1064	Deciphering the Colorectal Cancer Gut Microbiota: Association vs. Causality. **2019**, 15, 70-77		4
1063	Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis. *Cell Host and Microbe*, **2019**, 25, 285-299.e8	23.4	197
1062	Thirty Years of Lactobacillus rhamnosus GG: A Review. **2019**, 53 Suppl 1, S1-S41		90
1061	The Therapeutic Potential of the Yin-Yang Garden in Our Gut. **2019**,		1
1060	Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis. **2019**, 6, ofz463		4
1059	Pathogenicity and Drug Resistance of Human Pathogens. **2019**,		1
1058	Bacteria Co-colonizing with in Two Asymptomatic Patients. **2019**, 14, 628-637		1
1057	Reproducibility, stability, and accuracy of microbial profiles by fecal sample collection method in three distinct populations. **2019**, 14, e0224757		10
1056	Chronic obstructive pulmonary disease (COPD) and lung cancer: common pathways for pathogenesis. **2019**, 11, S2155-S2172		33
1055	Oral Microbiota as Promising Diagnostic Biomarkers for Gastrointestinal Cancer: A Systematic Review. **2019**, 12, 11131-11144		19
1054	ROS-mediated lipid peroxidation as a result of Cu(ii) interaction with FomA protein fragments of F. nucleatum: relevance to colorectal carcinogenesis. **2019**, 11, 2066-2077		9

1053	Gut Bacteria and their Metabolites: Which One Is the Defendant for Colorectal Cancer?. **2019**, 7,	14
1052	Prognostic impact of the Fusobacterium nucleatum status in colorectal cancers. **2019**, 98, e17221	17
1051	Characterization of the cecal microbiome composition of Wenchang chickens before and after fattening. **2019**, 14, e0225692	8
1050	Dietary Factors in the Control of Gut Homeostasis, Intestinal Stem Cells, and Colorectal Cancer. **2019**, 11,	11
1049	Nanotechnology intervention of the microbiome for cancer therapy. **2019**, 14, 1093-1103	87
1048	Role of the intestinal microbiome in colorectal cancer surgery outcomes. **2019**, 17, 204	17
1047	Impact of the gut microbiome on immune checkpoint inhibitor efficacy-a systematic review. **2019**, 26, 395-403	21
1046	Optimization of Culturomics Strategy in Human Fecal Samples. **2019**, 10, 2891	13
1045	Temporal Variability and Stability of the Fecal Microbiome: The Multiethnic Cohort Study. **2019**, 28, 154-162	20
1044	Fusobacterium nucleatum and colorectal cancer: A mechanistic overview. **2019**, 234, 2337-2344	49
1043	Environmental Factors, Gut Microbiota, and Colorectal Cancer Prevention. **2019**, 17, 275-289	89
1042	Integrating tumor genomics into studies of the microbiome in colorectal cancer. **2019**, 10, 547-552	10
1041	Analyzing the Secretome of Gut Microbiota as the Next Strategy For Early Detection of Colorectal Cancer. **2019**, 19, e1800176	2
1040	The role of gut microbiota in intestinal and liver diseases. **2019**, 53, 271-280	12
1039	The role of microbiota in the development of colorectal cancer. **2019**, 145, 2032-2041	43
1038	Obesity and cancer risk: Emerging biological mechanisms and perspectives. **2019**, 92, 121-135	330
1037	Alterations in the gut microbiota and metabolite profiles of thyroid carcinoma patients. **2019**, 144, 2728-2745	27
1036	Role of Oral Microbiota in Cancer Development. **2019**, 7,	143

1035	Microbiota and cancer: an update. **2019**, 31, 59-63	7
1034	Cellular Senescence: Aging, Cancer, and Injury. **2019**, 99, 1047-1078	245
1033	Interaction of bacteria and stem cells in health and disease. **2019**, 43, 162-180	6
1032	Fecal Fusobacterium nucleatum for the diagnosis of colorectal tumor: A systematic review and meta-analysis. **2019**, 8, 480-491	30
1031	Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms. **2019**, 247, 615-628	53
1030	Epigenetics and the Microbiome. **2019**, 79-103	
1029	Innate Sensing through Mesenchymal TLR4/MyD88 Signals Promotes Spontaneous Intestinal Tumorigenesis. **2019**, 26, 536-545.e4	19
1028	Prospective study of oral microbiome and colorectal cancer risk in low-income and African American populations. **2019**, 144, 2381-2389	43
1027	Heat stress mediates changes in fecal microbiome and functional pathways of laying hens. **2019**, 103, 461-472	66
1026	Differences in mortality in Fusobacterium necrophorum and Fusobacterium nucleatum infections detected by culture and 16S rRNA gene sequencing. **2019**, 38, 75-80	1
1025	The Microbiomes of Pancreatic and Duodenum Tissue Overlap and Are Highly Subject Specific but Differ between Pancreatic Cancer and Noncancer Subjects. **2019**, 28, 370-383	55
1024	Microbiota in cancer development and treatment. **2019**, 145, 49-63	42
1023	Fusobacterium nucleatum - symbiont, opportunist and oncobacterium. **2019**, 17, 156-166	304
1022	Aiding and Abetting: How the Tumor Microenvironment Protects Cancer from Chemotherapy. **2019**, 3, 409-428	7
1021	The intestinal microbiota associated with cardiac valve calcification differs from that of coronary artery disease. **2019**, 284, 121-128	28
1020	Intestinal microorganisms involved in colorectal cancer complicated with dyslipidosis. **2019**, 20, 81-89	21
1019	Progress in characterizing the linkage between Fusobacterium nucleatum and gastrointestinal cancer. **2019**, 54, 33-41	26
1018	Exploring Human Bacterial Diversity Toward Prevention of Infectious Disease and Health Promotion. **2019**, 519-533	4

1017	Targeting gut microbiota with dietary components on cancer: Effects and potential mechanisms of action. **2020**, 60, 1025-1037	40
1016	The vaginal microbiota, human papillomavirus and cervical dysplasia: a systematic review and network meta-analysis. **2020**, 127, 171-180	91
1015	Diet and Environment in Colorectal Cancer Development, Roles of. **2020**, 33-50	
1014	Impact of black raspberries on the normal and malignant Apc deficient murine gut microbiome. **2020**, 10, 61-76	6
1013	The antibody/microbiota interface in health and disease. **2020**, 13, 3-11	24
1012	Molecular Genetics and the Role of Molecularly Targeted Agents in Metastatic Colorectal Carcinoma. **2020**, 51, 387-400	6
1011	The Role of the Gut Microbiome in Colorectal Cancer: Where Are We? Where Are We Going?. **2020**, 19, 5-12	20
1010	Review article: bacteriophages in gastroenterology-from biology to clinical applications. **2020**, 51, 53-63	21
1009	Composition and diversity of the preputial microbiota in healthy bulls. **2020**, 145, 231-237	8
1008	Is periodontitis a risk indicator for gastrointestinal cancers? A meta-analysis of cohort studies. **2020**, 47, 134-147	5
1007	Developments in the study of gastrointestinal microbiome disorders affected by FGF19 in the occurrence and development of colorectal neoplasms. **2020**, 235, 4060-4069	2
1006	Autophagy of Intestinal Epithelial Cells Inhibits Colorectal Carcinogenesis Induced by Colibactin-Producing Escherichia coli in Apc Mice. **2020**, 158, 1373-1388	29
1005	promotes colorectal cancer metastasis by modulating /KRT7. **2020**, 11, 511-525	49
1004	The Role of the Cervicovaginal Microbiome on the Genesis and as a Biomarker of Premalignant Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer. **2019**, 21,	38
1003	. **2020**,	4
1002	Fecal microbiota as a noninvasive biomarker to predict the tissue iron accumulation in intestine epithelial cells and liver. **2020**, 34, 3006-3020	4
1001	Association of autophagy status with amount of Fusobacterium nucleatum in colorectal cancer. **2020**, 250, 397-408	16
1000	Dietary legumes, intestinal microbiota, inflammation and colorectal cancer. **2020**, 64, 103707	7

999	DNA sequence repeats identify numerous Type I restriction-modification systems that are potential epigenetic regulators controlling phase-variable regulons; phasevarions. **2020**, 34, 1038-1051	10
998	Long non-coding RNA ZEB1-AS1 promotes colon adenocarcinoma malignant progression via miR-455-3p/PAK2 axis. **2020**, 53, e12723	36
997	A novel faecal marker for the non-invasive diagnosis of colorectal adenoma and cancer. **2020**, 69, 1248-1257	70
996	Gut microbiota differences during metamorphosis in sick and healthy giant spiny frogs (Paa spinosa) tadpoles. **2020**, 70, 109-117	6
995	Characterization of tumor-infiltrating immune cells in relation to microbiota in colorectal cancers. **2020**, 69, 23-32	10
994	Characterizing the cancer-associated microbiome with small RNA sequencing data. **2020**, 522, 776-782	3
993	First steps towards combining faecal immunochemical testing with the gut microbiome in colorectal cancer screening. **2020**, 8, 293-302	10
992	The influence of the gastrointestinal microbiome on colorectal metastasis: a narrative review. **2020**, 22, 1101-1107	4
991	Promotes Metastasis in Colorectal Cancer by Activating Autophagy Signaling via the Upregulation of CARD3 Expression. **2020**, 10, 323-339	41
990	Roles of microbiota in response to cancer immunotherapy. **2020**, 65, 164-175	21
989	Regulation of host-microbe interactions at oral mucosal barriers by type 17 immunity. **2020**, 5,	51
988	FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2. **2020**, 39, 202	26
987	infection correlates with two types of microsatellite alterations in colorectal cancer and triggers DNA damage. **2020**, 12, 46	8
986	The Oral Microbiome and Cancer. **2020**, 11, 591088	33
985	Mucinous Adenocarcinoma of the Rectum: A Whole Genome Sequencing Study. **2020**, 10, 1682	3
984	Human oral microbiome dysbiosis as a novel non-invasive biomarker in detection of colorectal cancer. **2020**, 10, 11595-11606	14
983	A Potential Role for Stress-Induced Microbial Alterations in IgA-Associated Irritable Bowel Syndrome with Diarrhea. **2020**, 1,	8
982	Analysis of 16S rRNA genes reveals reduced Fusobacterial community diversity when translocating from saliva to GI sites. **2020**, 12, 1-13	3

981	Intestinal Microbiota in Colorectal Cancer Surgery. **2020**, 12,	12
980	Parvimonas micra as a putative non-invasive faecal biomarker for colorectal cancer. **2020**, 10, 15250	12
979	The Impact of Mushroom Polysaccharides on Gut Microbiota and Its Beneficial Effects to Host: A Review. **2020**, 250, 116942	31
978	Treatment of non-erosive reflux disease and dynamics of the esophageal microbiome: a prospective multicenter study. **2020**, 10, 15154	6
977	Use of the synbiotic VSL#3 and yacon-based concentrate attenuates intestinal damage and reduces the abundance of Candidatus Saccharimonas in a colitis-associated carcinogenesis model. **2020**, 137, 109721	9
976	Emerging role of immune checkpoint inhibitors and predictive biomarkers in head and neck cancers. **2020**, 109, 104977	3
975	Fusobacterium nucleatum is associated with worse prognosis in Lauren's diffuse type gastric cancer patients. **2020**, 10, 16240	18
974	Fusobacterium nucleatum promotes epithelial-mesenchymal transiton through regulation of the lncRNA MIR4435-2HG/miR-296-5p/Akt2/SNAI1 signaling pathway. **2020**, 287, 4032-4047	29
973	Opportunistic detection of Fusobacterium nucleatum as a marker for the early gut microbial dysbiosis. **2020**, 20, 208	18
972	Periodontal Diseases as Putative Risk Factors for Head and Neck Cancer: Systematic Review and Meta-Analysis. **2020**, 12,	15
971	Fusobacterium nucleatum, rectal cancer and radiotherapy. **2020**, 31, 1277-1278	
970	Bacteria pathogens drive host colonic epithelial cell promoter hypermethylation of tumor suppressor genes in colorectal cancer. **2020**, 8, 108	14
969	The role of the oral microbiota in chronic non-communicable disease and its relevance to the Indigenous health gap in Australia. **2020**, 20, 327	6
968	: the missing link for the cancer-preventive effect of. **2021**, 13, 1847629	11
967	Microbes in Tumoral In Situ Tissues and in Tumorigenesis. **2020**, 10, 572570	2
966	The Intestinal Microbiota and Colorectal Cancer. **2020**, 11, 615056	60
965	Detection of Fusobaterium nucleatum in feces and colorectal mucosa as a risk factor for colorectal cancer: a systematic review and meta-analysis. **2020**, 9, 276	8
964	Tissue-associated microbial detection in cancer using human sequencing data. **2020**, 21, 523	4

963	IRF3 prevents colorectal tumorigenesis via inhibiting the nuclear translocation of Ecatenin. **2020**, 11, 5762	15
962	Characteristics and differences of gut microbiota in patients with different Traditional Chinese Medicine Syndromes of Colorectal Cancer and normal population. **2020**, 11, 7357-7367	4
961	Signatures of Mucosal Microbiome in Oral Squamous Cell Carcinoma Identified Using a Random Forest Model. **2020**, 12, 5353-5363	4
960	Colon Cancer-Associated May Originate From the Oral Cavity and Reach Colon Tumors via the Circulatory System. **2020**, 10, 400	46
959	Multi-"-Omics" Profiling in Patients With Quiescent Inflammatory Bowel Disease Identifies Biomarkers Predicting Relapse. **2020**, 26, 1524-1532	11
958	Intestinal epithelial glycosylation in homeostasis and gut microbiota interactions in IBD. **2020**, 17, 597-617	45
957	host-cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration. **2020**, 13,	54
956	The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion. **2020**, 11, 1680	72
955	Bacterial invaders drive CRC progression. **2020**, 13,	1
954	The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy. **2020**, 12, 1083-1100	11
953	The gut microbiome and potential implications for early-onset colorectal cancer. **2020**, 9, CRC25	3
952	Pediatric Acute Lymphoblastic Leukemia Patients Exhibit Distinctive Alterations in the Gut Microbiota. **2020**, 10, 558799	13
951	Colon Carcinogenesis: The Interplay Between Diet and Gut Microbiota. **2020**, 10, 603086	16
950	S224 Presents a Catalytic Trade-off in PLP-Dependent l-Lanthionine Synthase from. **2020**, 59, 4250-4261	2
949	Bacteria associated with cockroaches: health risk or biotechnological opportunity?. **2020**, 104, 10369-10387	13
948	Effects of Fluorine on Intestinal Structural Integrity and Microbiota Composition of Common Carp. **2021**, 199, 3489-3496	3
947	Dysbiosis of the intestinal microbiota and colorectal cancer. **2020**, 135-155	1
946	Gut Microbiota and Colon Cancer: A Role for Bacterial Protein Toxins?. **2020**, 21,	14

945	Involvement of Species in Oral Cancer Progression: A Literature Review Including Other Types of Cancer. **2020**, 21,	20
944	The DNA Glycosylase NEIL2 Suppresses -Infection-Induced Inflammation and DNA Damage in Colonic Epithelial Cells. **2020**, 9,	11
943	The Macrophages-Microbiota Interplay in Colorectal Cancer (CRC)-Related Inflammation: Prognostic and Therapeutic Significance. **2020**, 21,	9
942	Host-microbiota maladaptation in colorectal cancer. **2020**, 585, 509-517	87
941	Darmmikrobiom bei primEren Hirntumoren. **2020**, 39, 31-39	
940	Knock down of BMSC-derived Wnt3a or its antagonist analogs attenuate colorectal carcinogenesis induced by chronic Fusobacterium nucleatum infection. **2020**, 495, 165-179	6
939	Microbiota and Cancer: The Emerging Beneficial Role of Bifidobacteria in Cancer Immunotherapy. **2020**, 11, 575072	14
938	Gut Microbiota-Mediated Inflammation and Gut Permeability in Patients with Obesity and Colorectal Cancer. **2020**, 21,	24
937	The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer. **2020**, 8, 1251-1261	45
936	Gut Microbiome and Its Impact on Health and Diseases. **2020**,	1
935	Bacteria-related changes in host DNA methylation and the risk for CRC. **2020**, 12, 1800898	2
934	Gut Microbiota Dysbiosis Drives the Development of Colorectal Cancer. **2021**, 102, 508-515	24
933	Catching a glimpse of the bacterial gut community of companion animals: a canine and feline perspective. **2020**, 13, 1708-1732	12
932	Modulation of pathogenic oral biofilms towards health with nisin probiotic. **2020**, 12, 1809302	14
931	Association or Causation? Exploring the Oral Microbiome and Cancer Links. **2020**, 99, 1411-1424	22
930	Bidirectional interaction between intestinal microbiome and cancer: opportunities for therapeutic interventions. **2020**, 8, 31	13
929	Targeting Gut Microbial Biofilms-A Key to Hinder Colon Carcinogenesis?. **2020**, 12,	13
928	Microbial Community Profiling Distinguishes Left-Sided and Right-Sided Colon Cancer. **2020**, 10, 498502	5

927	Could Periodontal Disease through Periopathogen be an Aggravating Factor for Gastric Cancer?. **2020**, 9,	3
926	A structurally unique Fusobacterium nucleatum tannase provides detoxicant activity against gallotannins and pathogen resistance. **2020**,	2
925	NF73-1 Isolated From NASH Patients Aggravates NAFLD in Mice by Translocating Into the Liver and Stimulating M1 Polarization. **2020**, 10, 535940	3
924	Microbiome in cancer progression and therapy. **2020**, 56, 118-126	4
923	Fate of Hematopoiesis During Aging. What Do We Really Know, and What are its Implications?. **2020**, 16, 1020-1048	13
922	Microbes and Cancer: Friends or Faux?. **2020**, 21,	11
921	Functionalization of Ti substrate with pH-responsive naringin-ZnO nanoparticles for the reconstruction of large bony after osteosarcoma resection. **2020**, 108, 2190-2205	12
920	Airway Microbiota as a Modulator of Lung Cancer. **2020**, 21,	16
919	The Alterations of Vaginal Microbiome in HPV16 Infection as Identified by Shotgun Metagenomic Sequencing. **2020**, 10, 286	7
918	Alteration in faecal bile acids, gut microbial composition and diversity after laparoscopic sleeve gastrectomy. **2020**, 107, 1673-1685	9
917	Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer. **2020**, 12,	19
916	Periodontal disease and cancer: Epidemiologic studies and possible mechanisms. **2020**, 83, 213-233	37
915	Adaptogenic flower buds exert cancer preventive effects by enhancing the SCFA-producers, strengthening the epithelial tight junction complex and immune responses. **2020**, 159, 104809	16
914	New Insights into Molecular Links Between Microbiota and Gastrointestinal Cancers: A Literature Review. **2020**, 21,	15
913	Bioinorganic hybrid bacteriophage for modulation of intestinal microbiota to remodel tumor-immune microenvironment against colorectal cancer. **2020**, 6, eaba1590	54
912	Structural analysis of the lipopolysaccharide O-antigen from strain CC 7/3 JVN3 C1 and development of a mouse monoclonal antibody specific to the O-antigen. **2020**, 66, 529-534	1
911	Therapeutic methods of gut microbiota modification in colorectal cancer management - fecal microbiota transplantation, prebiotics, probiotics, and synbiotics. **2020**, 11, 1518-1530	42
910	MinION Sequencing of colorectal cancer tumour microbiomes-A comparison with amplicon-based and RNA-Sequencing. **2020**, 15, e0233170	5

909	Microfluidics in Microbiome and Cancer Research. **2020**, 281-317	
908	The human tumor microbiome is composed of tumor type-specific intracellular bacteria. **2020**, 368, 973-980	379
907	The Bacterial Connection between the Oral Cavity and the Gut Diseases. **2020**, 99, 1021-1029	55
906	A review of cancer immunotherapy: from the past, to the present, to the future. **2020**, 27, S87-S97	182
905	Gut Microbiota-Based Algorithms in the Prediction of Metachronous Adenoma in Colorectal Cancer Patients Following Surgery. **2020**, 11, 1106	6
904	Toward Standards in Clinical Microbiota Studies: Comparison of Three DNA Extraction Methods and Two Bioinformatic Pipelines. **2020**, 5,	19
903	Bacteria as a double-action sword in cancer. **2020**, 1874, 188388	16
902	The Role of the Gut Microbiome in Colorectal Cancer Development and Therapy Response. **2020**, 12,	76
901	Host dysbiosis negatively impacts IL-9-producing T-cell differentiation and antitumour immunity. **2020**, 123, 534-541	7
900	Taxonomic and Functional Differences in Cervical Microbiome Associated with Cervical Cancer Development. **2020**, 10, 9720	15
899	Proteomic analysis of Fusobacterium nucleatum growth in biofilm versus planktonic state. **2020**, 35, 168-180	11
898	Challenges & opportunities for phage-based in situ microbiome engineering in the gut. **2020**, 326, 106-119	8
897	Human microbiome: an academic update on human body site specific surveillance and its possible role. **2020**, 202, 2147-2167	48
896	HARMONIES: A Hybrid Approach for Microbiome Networks Inference via Exploiting Sparsity. **2020**, 11, 445	2
895	The microbiome in pediatric oncology. **2020**, 126, 3629-3637	3
894	The critical role of Faecalibacterium prausnitzii in human health: An overview. **2020**, 149, 104344	37
893	Activates Endoplasmic Reticulum Stress to Promote Crohn's Disease Development the Upregulation of CARD3 Expression. **2020**, 11, 106	10
892	Host microbiomes and disease. **2020**, 122-153	0

891	Immune induction identified by TMT proteomics analysis in autoinducer-2 treated macrophages. **2020**, 17, 175-185	3
890	Parabacteroides distasonis attenuates tumorigenesis, modulates inflammatory markers and promotes intestinal barrier integrity in azoxymethane-treated A/J mice. **2020**, 41, 909-917	28
889	Mutational signature in colorectal cancer caused by genotoxic pks E. coli. **2020**, 580, 269-273	286
888	Colorectal cancer-associated anaerobic bacteria proliferate in tumor spheroids and alter the microenvironment. **2020**, 10, 5321	18
887	Gut bacteria affect the tumoral immune milieu: distorting the efficacy of immunotherapy or not?. **2020**, 11, 691-705	2
886	The landscape of bacterial presence in tumor and adjacent normal tissue across 9 major cancer types using TCGA exome sequencing. **2020**, 18, 631-641	16
885	The link "Cancer and autoimmune diseases" in the light of microbiota: Evidence of a potential culprit. **2020**, 222, 12-28	8
884	Characterization of the Esophageal Microbiota and Prediction of the Metabolic Pathways Involved in Esophageal Cancer. **2020**, 10, 268	16
883	Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression. **2020**, 11, 3259	84
882	The NF-Β Signaling Pathway, the Microbiota, and Gastrointestinal Tumorigenesis: Recent Advances. **2020**, 11, 1387	33
881	A fluorescence quenching-recovery sensor based on RCA for the specific analysis of Fusobacterium nucleatum. nucleatum. **2020**, 604, 113808	2
880	Gut microbiome, big data and machine learning to promote precision medicine for cancer. **2020**, 17, 635-648	64
879	The deubiquitinase USP25 supports colonic inflammation and bacterial infection and promotes colorectal cancer.. **2020**, 1, 811-825	11
878	Role of the oral microbiota in cancer evolution and progression. **2020**, 9, 6306-6321	30
877	Modulation of Anti-Tumour Immune Responses by Probiotic Bacteria. **2020**, 8,	9
876	Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-augmented Clinical Trials. **2020**, 16, 81-88	9
875	Potential Use of Biotherapeutic Bacteria to Target Colorectal Cancer-Associated Taxa. **2020**, 21,	10
874	Southern Chinese populations harbour non-nucleatum Fusobacteria possessing homologues of the colorectal cancer-associated FadA virulence factor. **2020**, 69, 1998-2007	16

873	From Beyond the Pale to the Pale Riders: The Emerging Association of Bacteria with Oral Cancer. **2020**, 99, 604-612	19
872	Gastric and duodenal ulcers, periodontal disease, and risk of bladder cancer in the Health Professionals Follow-up Study. **2020**, 31, 383-391	3
871	Microbiome in Colorectal Cancer: How to Get from Meta-omics to Mechanism?. **2020**, 28, 401-423	58
870	Foes or Friends? Bacteria Enriched in the Tumor Microenvironment of Colorectal Cancer. **2020**, 12,	13
869	Colibactin-positive Escherichia coli induce a procarcinogenic immune environment leading to immunotherapy resistance in colorectal cancer. **2020**, 146, 3147-3159	22
868	BGN/TLR4/NF-B Mediates Epigenetic Silencing of Immunosuppressive Siglec Ligands in Colon Cancer Cells. **2020**, 9,	15
867	in the Colorectum and Its Association with Cancer Risk and Survival: A Systematic Review and Meta-analysis. **2020**, 29, 539-548	33
866	The Association of Post-Stroke Cognitive Impairment and Gut Microbiota and its Corresponding Metabolites. **2020**, 73, 1455-1466	23
865	Establishing high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in patients with healthy families. **2020**, 11, 918-929	14
864	Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growth. **2020**, 5, 511-524	104
863	The Influence of Lung Microbiota on Lung Carcinogenesis, Immunity, and Immunotherapy. **2020**, 6, 86-97	50
862	The mutual interplay of gut microbiota, diet and human disease. **2020**, 287, 833-855	75
861	Detection of Fusobacterium in oral and head and neck cancer samples: A systematic review and meta-analysis. **2020**, 112, 104669	20
860	Fusobacterium bloodstream infections: A literature review and hospital-based case series. **2020**, 62, 102165	7
859	The impact of the gut microbiota on prognosis after surgery for colorectal cancer - a systematic review and meta-analysis. **2020**, 128, 162-176	8
858	Significance of the gut microbiome in multistep colorectal carcinogenesis. **2020**, 111, 766-773	27
857	Structure of the Mucosal and Stool Microbiome in Lynch Syndrome. *Cell Host and Microbe*, **2020**, 27, 585-600.e4	20
856	The microbiome in rheumatology: Where are we and where should we go?. **2020**, 79, 727-733	33

855	Alterations of the Predominant Fecal Microbiota and Disruption of the Gut Mucosal Barrier in Patients with Early-Stage Colorectal Cancer. **2020**, 2020, 2948282	15
854	Toxicomicrobiomics: The Human Microbiome vs. Pharmaceutical, Dietary, and Environmental Xenobiotics. **2020**, 11, 390	27
853	Protocol of proceedings with and optimization of ABTS method for detection of reactive oxygen species. **2020**, 15, 259-271	2
852	Intestinal microbiota and its association with colon cancer and red/processed meat consumption. **2021**, 36, 75-88	33
851	Molecular mechanisms of postbiotics in colorectal cancer prevention and treatment. **2021**, 61, 1787-1803	28
850	Microbiome and host crosstalk: A new paradigm to cancer therapy. **2021**, 70, 71-84	8
849	Emerging role of microbiota in immunomodulation and cancer immunotherapy. **2021**, 70, 37-52	3
848	Differential immune microenvironmental features of microsatellite-unstable colorectal cancers according to Fusobacterium nucleatum status. **2021**, 70, 47-59	8
847	Gut microbiota contributes towards immunomodulation against cancer: New frontiers in precision cancer therapeutics. **2021**, 70, 11-23	9
846	Bugs as drugs: The role of microbiome in cancer focusing on immunotherapeutics. **2021**, 92, 102125	5
845	Fecal microbial DNA markers serve for screening colorectal neoplasm in asymptomatic subjects. **2021**, 36, 1035-1043	6
844	Tripartite relationship between gut microbiota, intestinal mucus and dietary fibers: towards preventive strategies against enteric infections. **2021**, 45,	13
843	Microbiota Effects on Carcinogenesis: Initiation, Promotion, and Progression. **2021**, 72, 243-261	13
842	Production of hydrogen sulfide by the intestinal microbiota and epithelial cells and consequences for the colonic and rectal mucosa. **2021**, 320, G125-G135	14
841	Is periodontal disease associated with increased risk of colorectal cancer? A meta-analysis. **2021**, 19, 50-61	10
840	The microbiome, genetics, and gastrointestinal neoplasms: the evolving field of molecular pathological epidemiology to analyze the tumor-immune-microbiome interaction. **2021**, 140, 725-746	12
839	Microbiome and Cervical Cancer. **2021**, 88, 187-197	11
838	Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy. **2021**, 160, 600-613	41

837	Heterogeneous distribution of Fusobacterium nucleatum in the progression of colorectal cancer. **2021**, 36, 1869-1876	7
836	Is periodontal disease a risk indicator for colorectal cancer? A systematic review and meta-analysis. **2021**, 48, 336-347	8
835	Unexpected guests in the tumor microenvironment: microbiome in cancer. **2021**, 12, 426-435	25
834	Role of gut microbiota in epigenetic regulation of colorectal Cancer. **2021**, 1875, 188490	8
833	Postbiotics: Metabolites and mechanisms involved in microbiota-host interactions. **2021**, 108, 11-26	18
832	Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma. **2021**, 124, 963-974	12
831	Gut Microbiome Components Predict Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Prospective, Longitudinal Study. **2021**, 27, 1329-1340	20
830	The Role of Fusobacterium nucleatum in Colorectal Carcinogenesis. **2021**, 88, 127-140	8
829	Effect of probiotics and gut microbiota on anti-cancer drugs: Mechanistic perspectives. **2021**, 1875, 188494	21
828	Fusobacteria modulate oral carcinogenesis and promote cancer progression. **2020**, 13, 1849493	19
827	Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer's disease. **2021**, 264, 118627	65
826	Gut microbiota targeted nanomedicine for cancer therapy: Challenges and future considerations. **2021**, 107, 240-251	11
825	The role of the microbiome in drug resistance in gastrointestinal cancers. **2021**, 21, 165-176	6
824	Exposure of lead on intestinal structural integrity and the diversity of gut microbiota of common carp. **2021**, 239, 108877	13
823	Roles of the Polyphenol-Gut Microbiota Interaction in Alleviating Colitis and Preventing Colitis-Associated Colorectal Cancer. **2021**, 12, 546-565	26
822	Alteration of fecal microbiota by fucoxanthin results in prevention of colorectal cancer in AOM/DSS mice. **2021**, 42, 210-219	15
821	Relationship Between Microbiome and Colorectal Cancer. **2021**, 568-578	1
820	Gut Microbiota-Derived Epigenetic Alterations During Onset of Diseases. **2022**, 223-223	

819	Role of the Microbiome in Pancreatic Cancer. **2021**, 267-285	
818	Integration of constraint-based modeling with fecal metabolomics reveals large deleterious effects of spp. on community butyrate production. **2021**, 13, 1-23	5
817	Significant and Conflicting Correlation of IL-9 With and in Human Colorectal Cancer. **2020**, 11, 573158	7
816	What is the future of Periodontal Medicine?. **2021**, 35, e102	2
815	The Gut Microbiome and Colorectal Cancer. **2021**, 63-96	0
814	Microbiome-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer.	1
813	Local and systemic mechanisms linking periodontal disease and inflammatory comorbidities. **2021**, 21, 426-440	117
812	Modeling colorectal cancers using multidimensional organoids. **2021**, 151, 345-383	1
811	A type VII secretion system of Streptococcus gallolyticus subsp. gallolyticus contributes to gut colonization and the development of colon tumors. **2021**, 17, e1009182	12
810	High fat diet, gut microbiome and gastrointestinal cancer. **2021**, 11, 5889-5910	5
809	Butyrate-producing human gut symbiont, , and its role in health and disease. **2021**, 13, 1-28	23
808	The Microbiome and Urologic Cancers. **2021**, 257-270	
807	Gut Microbiome and Cancer. **2021**, 93-168	
806	HNU082 inhibited the growth of and alleviated the inflammatory response introduced by invasion. **2021**, 12, 10728-10740	2
805	Diagnostic Evaluation of Streptococcus gallolyticus Infection in Patients with Colon Diseases by PCR Method. **2021**, 23,	
804	Altered gut microbiota correlate with different immune responses to HAART in HIV-infected individuals. **2021**, 21, 11	9
803	Treg Cells and Epigenetic Regulation. **2021**, 1278, 95-114	3
802	From taxonomy to metabolic output: what factors define gut microbiome health?. **2021**, 13, 1-20	3

801	Oral Complications of Dental Prosthetic for Patients after Chemotherapy and Radiotherapy Treatment. **2021**, 12, 67	
800	"Driver-passenger" bacteria and their metabolites in the pathogenesis of colorectal cancer. **2021**, 13, 1941710	7
799	The Role of Gut Microbiota Dysbiosis in Gastrointestinal Carcinogenesis. **2021**,	
798	Nod1 promotes colorectal carcinogenesis by regulating the immunosuppressive functions of tumor-infiltrating myeloid cells. **2021**, 34, 108677	18
797	Diet, Microbiome, Inflammation, and Cancer. **2021**, 329-348	
796	Immune System Efficiency in Cancer and the Microbiota Influence. **2021**, 88, 170-186	5
795	Microbiome changes in aging. **2021**, 367-389	
794	Gold digging: Searching for gut microbiota that enhances´antitumor immunity. **2021**, 236, 5495-5511	1
793	Recent Therapeutic Strategies for the Treatment of Colon Cancer. **2021**, 73-90	
792	Colorectal Cancer. **2021**, 1963-1989	
791	Colon Cancer Screening and Surveillance in the IBD Patient. **2021**, 245-263	
790	The oralome and its dysbiosis: New insights into oral microbiome-host interactions. **2021**, 19, 1335-1360	45
789	Microbiome and the Hallmarks of Cancer. **2021**, 1-26	1
788	Exploring the Role of Gut Microbiome in Colon Cancer. **2021**, 193, 1780-1799	13
787	Immunotherapy in colorectal cancer. **2021**, 151, 137-196	6
786	Fiber-associated Lachnospiraceae reduce colon tumorigenesis by modulation of the tumor-immune microenvironment.	1
785	Stem Cell Impairment at the Host-Microbiota Interface in Colorectal Cancer. **2021**, 13,	5
784	Risk of Colorectal Cancer in Patients With Attention-Deficit Hyperactivity Disorder: A Nationwide, Population-Based Cohort Study. **2021**, 12, 537137	

783	Cadherin-mediated host-pathogen interactions. **2021**, 23, e13316		1
782	New Insights Into the Cancer-Microbiome-Immune Axis: Decrypting a Decade of Discoveries. **2021**, 12, 622064		28
781	Salivary microbiota may predict the presence of esophageal squamous cell carcinoma. **2021**,		2
780	Association of with Specific T-cell Subsets in the Colorectal Carcinoma Microenvironment. **2021**, 27, 2816-2826		12
779	Advances in Modeling the Immune Microenvironment of Colorectal Cancer. **2020**, 11, 614300		5
778	Intestinal bacteria are potential biomarkers and therapeutic targets for gastric cancer. **2021**, 151, 104747		7
777	Bacterial associations in the healthy human gut microbiome across populations. **2021**, 11, 2828		13
776	The cancer microbiome atlas: a pan-cancer comparative analysis to distinguish tissue-resident microbiota from contaminants. *Cell Host and Microbe*, **2021**, 29, 281-298.e5	23.4	22
775	Parvimonas micra, Peptostreptococcus stomatis, Fusobacterium nucleatum and Akkermansia muciniphila as a four-bacteria biomarker panel of colorectal cancer. **2021**, 11, 2925		22
774	Strain-Specific Enhances the Efficacy of Cancer Therapeutics in Tumor-Bearing Mice. **2021**, 13,		8
773	The association between Fusobacterium nucleatum and cancer colorectal: a systematic review and meta-analysis. **2021**,		1
772	Tumor-Associated Microbiota in Esophageal Squamous Cell Carcinoma. **2021**, 9, 641270		8
771	Cancer Microbiome; Opportunities and Challenges. **2021**, 21, 215-229		1
770	Tumor-Associated Microbiome: Where Do We Stand?. **2021**, 22,		9
769	A Fold Type II PLP-Dependent Enzyme from Functions as a Serine Synthase and Cysteine Synthase. **2021**, 60, 524-536		0
768	Interconnections Between the Oral and Gut Microbiomes: Reversal of Microbial Dysbiosis and the Balance Between Systemic Health and Disease. **2021**, 9,		16
767	Microbial Characteristics of Locally Advanced Rectal Cancer Patients After Neoadjuvant Chemoradiation Therapy According to Pathologic Response. **2021**, 13, 2655-2667		0
766	Role of intestinal microbiota in colorectal carcinogenesis (review). **2021**, 20, 68-76		

765	Advances in bulk and single-cell multi-omics approaches for systems biology and precision medicine. **2021**, 22,	3
764	Gut Microbiota: Influence on Carcinogenesis and Modulation Strategies by Drug Delivery Systems to Improve Cancer Therapy. **2021**, 8, 2003542	8
763	Characteristics of the gut microbiome profile in obese patients with colorectal cancer. **2021**, 5, 498-507	4
762	Microbial Metabolites in Colorectal Cancer: Basic and Clinical Implications. **2021**, 11,	12
761	Identification of bacteria-derived HLA-bound peptides in melanoma. **2021**, 592, 138-143	52
760	Consumption of Select Dietary Emulsifiers Exacerbates the Development of Spontaneous Intestinal Adenoma. **2021**, 22,	8
759	Fusobacterium nucleatum impedes remission of colitis in a mouse model. **2021**, 85, 1235-1242	3
758	Fecal microbiota changes with fermented kimchi intake regulated either formation or advancement of colon adenoma. **2021**, 68, 139-148	3
757	Approaching precision medicine by tailoring the microbiota. **2021**, 32, 206-222	
756	Heat stress on microbiota composition, barrier integrity, and nutrient transport in gut, production performance, and its amelioration in farm animals. **2021**, 63, 211-247	12
755	Drug-Microbiota Interaction in Colon Cancer Therapy: Impact of Antibiotics. **2021**, 9,	3
754	The Potential of Colonic Tumor Tissue to Predict Staging and Its Interplay with Oral Abundance in Colon Cancer Patients. **2021**, 13,	6
753	Association of periodontitis and tooth loss with liver cancer: A systematic review. **2021**, 159, 103221	3
752	Promotes Colorectal Carcinoma by Activating the Hematopoietic Inflammasome. **2021**, 81, 2745-2759	19
751	Role of the Gastric Microbiome in Gastric Cancer: From Carcinogenesis to Treatment. **2021**, 12, 641322	14
750	Immune System, Microbiota, and Microbial Metabolites: The Unresolved Triad in Colorectal Cancer Microenvironment. **2021**, 12, 612826	16
749	Bacteriophage manipulation of the microbiome associated with tumour microenvironments-can this improve cancer therapeutic response?. **2021**, 45,	2
748	and as Major Microbiota in Mesotheliomas. **2021**, 11,	0

747	Oral Gut Microbiome Axis in Gastrointestinal Disease and Cancer. **2021**, 13, 1748	0
746	The dysbiosis signature of Fusobacterium nucleatum in colorectal cancer-cause or consequences? A systematic review. **2021**, 21, 194	15
745	Modulating host gene expression via gut microbiome-microRNA interplay to treat human diseases. **2021**, 47, 596-611	0
744	Gut microbes in gastrointestinal cancers. **2021**,	2
743	Luminescent Phage-Based Detection of : From Engineering to Diagnostics. **2021**, 14,	1
742	The Role of Intestinal Microbiota in Colorectal Cancer. **2021**, 12, 674807	4
741	The onco-immunological implications of Fusobacterium nucleatum in breast cancer. **2021**, 232, 60-66	3
740	Non-small cell lung cancer microbiota characterization: Prevalence of enteric and potentially pathogenic bacteria in cancer tissues. **2021**, 16, e0249832	2
739	The Role of Gut Barrier Dysfunction and Microbiome Dysbiosis in Colorectal Cancer Development. **2021**, 11, 626349	14
738	The link among microbiota, epigenetics, and disease development. **2021**, 28, 28926-28964	4
737	Microbiome: an old history of a new paradigm. **2021**,	0
736	Oral-Gut Microbiome Axis in Gastrointestinal Disease and Cancer. **2021**, 13,	17
735	Secretes Outer Membrane Vesicles and Promotes Intestinal Inflammation. **2021**, 12,	17
734	Aspirin Modulation of the Colorectal Cancer-Associated Microbe Fusobacterium nucleatum. **2021**, 12,	6
733	Environmental Influences on the Human Microbiome and Implications for Noncommunicable Disease. **2021**, 42, 277-292	7
732	Patients with mesenchymal tumours and high Fusobacteriales prevalence have worse prognosis in colorectal cancer (CRC).	1
731	Potential of fecal microbiota for detection and postoperative surveillance of colorectal cancer. **2021**, 21, 156	2
730	Modulation of the host cell transcriptome and epigenome by Fusobacterium nucleatum.	

729	The association between obesity and weight loss after bariatric surgery on the vaginal microbiota. **2021**, 9, 124	3
728	Proteomics, Personalized Medicine and Cancer. **2021**, 13,	9
727	Metagenomic Analysis of Common Intestinal Diseases Reveals Relationships among Microbial Signatures and Powers Multidisease Diagnostic Models. **2021**, 6,	5
726	The role of microbiome in colorectal carcinogenesis and its clinical potential as a target for cancer treatment. **2021**,	6
725	It takes a village: microbiota, parainflammation, paligenosis and bystander effects in colorectal cancer initiation. **2021**, 14,	1
724	A Comprehensive Overview of Colon Cancer- A Grim Reaper of the 21st Century. **2021**, 28, 2657-2696	4
723	Role of Gut Microbiota and Probiotics in Colorectal Cancer: Onset and Progression. **2021**, 9,	13
722	Microbe-based therapies for colorectal cancer: Advantages and limitations. **2021**,	5
721	Profiling of tumour-associated microbiota in human hepatocellular carcinoma. **2021**, 11, 10589	4
720	Maternal Microbiota, Early Life Colonization and Breast Milk Drive Immune Development in the Newborn. **2021**, 12, 683022	10
719	Low-Abundant Microorganisms: The Human Microbiome's Dark Matter, a Scoping Review. **2021**, 11, 689197	4
718	A clinical nomogram incorporating salivary level and oral hygiene index for predicting colorectal cancer. **2021**, 9, 754	2
717	Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes. **2021**, 22,	4
716	Facilitates M2 Macrophage Polarization and Colorectal Carcinoma Progression by Activating TLR4/NF-B/S100A9 Cascade. **2021**, 12, 658681	7
715	Fusobacterium nucleatum secretes amyloid-like FadA to enhance pathogenicity. **2021**, 22, e52891	11
714	Pathogens and Carcinogenesis: A Review. **2021**, 10,	7
713	Exploiting the Acidic Extracellular pH: Evaluation of Streptococcus salivarius M18 Postbiotics to Target Cancer Cells. **2021**, 1	3
712	Mediterranean Diet to Prevent the Development of Colon Diseases: A Meta-Analysis of Gut Microbiota Studies. **2021**, 13,	6

711	Familial adenomatous polyposis and changes in the gut microbiota: New insights into colorectal cancer carcinogenesis. **2021**, 13, 495-508	3
710	At the right time in the right place: How do luminal gradients position the microbiota along the gut?. **2021**, 203712	3
709	Microbiota and cancer (review of literature). **2021**, 27, 14-27	
708	Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies. **2021**, 13,	5
707	The relationship between gastrointestinal cancers and the microbiota. **2021**, 6, 498-509	4
706	Microbial Community Heterogeneity Within Colorectal Neoplasia and its Correlation With Colorectal Carcinogenesis. **2021**, 160, 2395-2408	15
705	Highlighting the Relevance of Gut Microbiota Manipulation in Inflammatory Bowel Disease. **2021**, 11,	16
704	Microbiome and colorectal cancer: A review of the past, present, and future. **2021**, 37, 101560	3
703	Antibiotic use and colorectal neoplasia: a systematic review and meta-analysis. **2021**, 8,	4
702	Association of Fusobacterium nucleatum in the Progression of Colorectal Cancer. **2021**, 51, 39-53	
701	Toll-like receptor 5 and 8 in hepatocellular carcinoma. **2021**, 129, 470-479	1
700	Association of Fusobacterium nucleatum infection and colorectal cancer: A Mexican study. **2021**,	
699	Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients. **2021**, 112, 3005-3017	5
698	Proliferative Effect of FadA Recombinant Protein from Fusobacterium nucleatum on SW480 Colorectal Cancer Cell Line. **2021**, 21, 623-628	4
697	Genetic and molecular determinants of polymicrobial interactions in. **2021**, 118,	9
696	Fecal Fusobacterium nucleatum as a predictor for metachronous colorectal adenoma after endoscopic polypectomy. **2021**, 36, 2841-2849	2
695	Oral microbiome and pregnancy: A bidirectional relationship. **2021**, 145, 103293	8
694	The pathogenic oral-gut-liver axis: new understandings and clinical implications. **2021**, 17, 727-736	3

693	Association of Fusobacterium nucleatum in the Progression of Colorectal Cancer. **2021**, 51, 39-53	
692	Contribution of the microbiota and their secretory products to inflammation and colorectal cancer pathogenesis: the role of toll-like receptors. **2021**, 42, 1133-1142	4
691	Diversity and distribution of sulfur metabolism in the human gut microbiome and its association with colorectal cancer.	1
690	Prognostic Significance of the Number of Teeth in Patients with Colorectal Cancer. **2021**, 5, 237-246	0
689	Microbial Associations with Pancreatic Cancer: A New Frontier in Biomarkers. **2021**, 13,	6
688	Bile Acids, Their Receptors, and the Gut Microbiota. **2021**, 36, 235-245	4
687	Disruption of Metallostasis in the Anaerobic Human Pathogen by the Zinc Ionophore PBT2. **2021**, 7, 2285-2298	1
686	Gut microbiota-mediated immunomodulation in tumor. **2021**, 40, 221	7
685	Gut Microbiota in Cancer Immune Response and Immunotherapy. **2021**, 7, 647-660	19
684	The diverse roles of myeloid derived suppressor cells in mucosal immunity. **2021**, 365, 104361	4
683	Metabolites of the Oral Microbiome: Important Mediators of Multi-Kingdom Interactions. **2021**,	1
682	Colorectal Cancer Patients Have Four Specific Bacterial Species in Oral and Gut Microbiota in Common-A Metagenomic Comparison with Healthy Subjects. **2021**, 13,	3
681	Mice, Models, Microbiota: How Can We More Accurately Reflect Human Disease?. **2021**, 15, 8	
680	The Impact of Long-Term Antibiotic Therapy of Cutaneous Adverse Reactions to EGFR Inhibitors in Colorectal Cancer Patients. **2021**, 10,	4
679	Nutritional Interventions Targeting Gut Microbiota during Cancer Therapies. **2021**, 9,	1
678	The Fruits of Inhibit Colorectal Cancer Cell Migration Induced by -Derived Extracellular Vesicles. **2021**, 26,	2
677	Gut microbiota-derived metabolites in CRC progression and causation. **2021**, 147, 3141-3155	5
676	Multifaceted Impacts of Periodontal Pathogens in Disorders of the Intestinal Barrier. **2021**, 12, 693479	1

675	Alterations, Interactions, and Diagnostic Potential of Gut Bacteria and Viruses in Colorectal Cancer. **2021**, 11, 657867	8
674	Bacterial cyclomodulins: types and roles in carcinogenesis. **2021**, 1-25	1
673	Recent advancements in the exploitation of the gut microbiome in the diagnosis and treatment of colorectal cancer. **2021**, 41,	2
672	Association of Fusobacterium nucleatum infection and colorectal cancer: A Mexican study. **2021**,	0
671	Genomic, Microbial and Immunological Microenvironment of Colorectal Polyps. **2021**, 13,	0
670	Colorectal cancer treatment using bacteria: focus on molecular mechanisms. **2021**, 21, 218	5
669	Pathological and Therapeutic Approach to Endotoxin-Secreting Bacteria Involved in Periodontal Disease. **2021**, 13,	4
668	CEACAM1 Activation by CbpF-Expressing. **2021**, 11, 699015	0
667	Microbiome and gastrointestinal malignancies. **2021**, 22, 100451	1
666	The Sulfur Microbial Diet and Risk of Colorectal Cancer by Molecular Subtypes and Intratumoral Microbial Species in Adult Men. **2021**, 12, e00338	1
665	Microbiota-Associated Metabolites and Related Immunoregulation in Colorectal Cancer. **2021**, 13,	0
664	Low Abundance Supports Early Pregnancy Development - An Study. **2021**, 12, 698045	1
663	Cyanidin-3--glucoside and its phenolic metabolites ameliorate intestinal diseases via modulating intestinal mucosal immune system: potential mechanisms and therapeutic strategies. **2021**, 1-19	3
662	Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review). **2021**, 59,	4
661	Tumor-Associated Macrophages (TAMs) in Colorectal Cancer (CRC): From Mechanism to Therapy and Prognosis. **2021**, 22,	15
660	Fecal Fusobacterium nucleatum harbored virulence gene fadA are associated with ulcerative colitis and clinical outcomes. **2021**, 157, 104964	5
659	Precision strategies for cancer treatment by modifying the tumor-related bacteria. **2021**, 105, 6183-6197	2
658	Acts as a Pro-carcinogenic Bacterium in Colorectal Cancer: From Association to Causality. **2021**, 9, 710165	12

657	Possible Immunotherapeutic Strategies Based on Carcinogen-Dependent Subgroup Classification for Oral Cancer. **2021**, 8, 717038	0
656	The impact of the host intestinal microbiome on carcinogenesis and the response to chemotherapy. **2021**, 17, 4371-4387	1
655	Higher titer hepatitis B core antibody predicts a higher risk of liver metastases and worse survival in patients with colorectal cancer. **2021**, 19, 251	0
654	Metagenomic analysis revealed the potential role of gut microbiome in gout. **2021**, 7, 66	15
653	The Cancer Microbiome: Recent Highlights and Knowledge Gaps. **2021**, 11, 2378-2395	5
652	Paradigm shift in the pathogenesis and treatment of oral cancer and other cancers focused on the oralome and antimicrobial-based therapeutics. **2021**, 87, 76-93	7
651	Modulation of the Mucosa-Associated Microbiome Linked to the PTPN2 Risk Gene in Patients with Primary Sclerosing Cholangitis and Ulcerative Colitis. **2021**, 9,	0
650	Harness the functions of gut microbiome in tumorigenesis for cancer treatment. **2021**, 41, 937-967	1
649	Gut Microbiota Profiles in Early- and Late-Onset Colorectal Cancer: A Potential Diagnostic Biomarker in the Future. **2021**, 102, 823-832	4
648	Invasive Pathobionts Contribute to Colon Cancer Initiation by Counterbalancing Epithelial Antimicrobial Responses. **2021**, 13, 57-79	4
647	Microbiome and Cancer Immunotherapy. **2021**, 96, 312-317	
646	Association of Polygenic Risk Score and Bacterial Toxins at Screening Colonoscopy with Colorectal Cancer Progression: A Multicenter Case-Control Study. **2021**, 13,	3
645	Differential Mucosal Microbiome Profiles across Stages of Human Colorectal Cancer. **2021**, 11,	4
644	Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma. **2021**,	12
643	Wolf in Sheep's Clothing: Biofilm as a Reservoir for Recurrent Infections. **2021**, 9,	4
642	MetaGeneBank: a standardized database to study deep sequenced metagenomic data from human fecal specimen. **2021**, 21, 263	0
641	An international report on bacterial communities in esophageal squamous cell carcinoma.	
640	The Role of Microbiota in Gastrointestinal Cancer and Cancer Treatment - Chance or Curse?. **2021**,	4

639	Engineering of a Hollow-Structured Cu2XS Nano-Homojunction Platform for Near Infrared-Triggered Infected Wound Healing and Cancer Therapy. 2106700	13
638	Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy. **2021**, 39, 1202-1213.e6	27
637	Microbiota and Colorectal Cancer: From Gut to Bedside. **2021**, 12, 760280	2
636	Monocarboxylate Transporter-2 Expression Restricts Tumor Growth in a Murine Model of Lung Cancer: A Multi-Omic Analysis. **2021**, 22,	2
635	A Statistical Framework for Data Purification with Application to Microbiome Data Analysis.	
634	Patients with mesenchymal tumours and high prevalence have worse prognosis in colorectal cancer (CRC). **2021**,	2
633	Microbiome and cancer. **2021**, 39, 1317-1341	18
632	Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion. **2021**, 12, 5674	19
631	Relationship between Fusobacterium nucleatum and antitumor immunity in colorectal cancer liver metastasis. **2021**, 112, 4470-4477	4
630	Metatranscriptomic Analysis of Human Lung Metagenomes from Patients with Lung Cancer. **2021**, 12,	2
629	Interaction between intestinal microbiota and tumour immunity in the tumour microenvironment. **2021**, 164, 476-493	6
628	The possible mechanism of gastrointestinal cancer development and progression by periodontopathogenic bacteria. **2021**, 63, 151-157	
627	Colorectal Tumour Mucosa Microbiome Is Enriched in Oral Pathogens and Defines Three Subtypes That Correlate with Markers of Tumour Progression. **2021**, 13,	1
626	Bacterial genotoxin accelerates transient infection-driven murine colon tumorigenesis. **2021**,	5
625	Fusobacterium nucleatum and Clinicopathologic Features of Colorectal Cancer: Results From the ColoCare Study. **2021**, 20, e165-e172	6
624	Impact of Appendectomy on Gut Microbiota. **2021**, 22, 651-661	4
623	Tumor models to assess immune response and tumor-microbiome interactions in colorectal cancer. **2021**, 231, 107981	2
622	Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?. **2021**, 22, 1-12	6

621	Cancer-fighting potentials of algal polysaccharides as nutraceuticals. **2021**, 147, 110522	8
620	Microscale communication between bacterial pathogens and the host epithelium. **2021**, 22, 247-254	0
619	Tumor-Associated Microbiota in Proximal and Distal Colorectal Cancer and Their Relationships With Clinical Outcomes. **2021**, 12, 727937	2
618	Siglec-7 Mediates Immunomodulation by Colorectal Cancer-Associated ssp.. **2021**, 12, 744184	0
617	Negative impacts of microcystin-LR and glyphosate on zebrafish intestine: Linked with gut microbiota and microRNAs?. **2021**, 286, 117685	11
616	Fusobacterium nucleatum - Friend or foe?. **2021**, 224, 111586	4
615	Gut Microbiota and Colorectal Cancer. **2022**, 357-357	
614	Inflammation and cancer. **2022**, 63-82	0
613	The Viral Janus: Viruses as Aetiological Agents and Treatment Options in Colorectal Cancer. **2020**, 10, 601573	4
612	Alterations of bacterial communities of vocal cord mucous membrane increases the risk for glottic laryngeal squamous cell carcinoma. **2021**, 12, 4049-4063	3
611	Nutrition as a Key Modifiable Factor for Periodontitis and Main Chronic Diseases. **2021**, 10,	16
610	Metagenomic Analyses Expand Bacterial and Functional Profiling Biomarkers for Colorectal Cancer in a Hainan Cohort, China. **2021**, 78, 705-712	6
609	Fecal Markers Streptococcus Anginosus and Streptococcus Constellatus for Non-Invasive Screening and Early Warning of Gastric Cancer.	
608	Dysbiosis Triggers ACF Development in Genetically Predisposed Subjects. **2021**, 13,	3
607	Phytoproteomics. **2021**, 15-31	
606	MHC Phosphopeptides: Promising Targets for Immunotherapy of Cancer and Other Chronic Diseases. **2021**, 20, 100112	2
605	Gastrointestinal biofilms in health and disease. **2021**, 18, 314-334	42
604	Gut Microbial Signatures in Sporadic and Hereditary Colorectal Cancer. **2021**, 22,	2

603	Microbiome as an Immunological Modifier. **2020**, 2055, 595-638	8
602	The Function of the Oral Microbiome in Health and Disease. **2020**, 141-173	4
601	Epigenetics and the Microbiome. **2017**, 1-25	1
600	Salivary Diagnostics and the Oral Microbiome. **2015**, 83-119	3
599	On the Search to Elucidate the Role of Microbiota in the Genesis of Cancer: The Cases of Gastrointestinal and Cervical Cancer. **2017**, 48, 754-765	14
598	Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells. **2020**, 181, 1263-1275.e16	166
597	AI finds microbial signatures in tumours and blood across cancer types. **2020**, 579, 502-503	1
596	Serrated neoplasia in the colorectum: gut microbiota and molecular pathways. **2021**, 13, 1-12	2
595	An overview of cancer health disparities: new approaches and insights and why they matter. **2021**, 42, 2-13	11
594	Rapid detection of nusG and fadA in Fusobacterium nucleatum by loop-mediated isothermal amplification. **2016**, 65, 760-769	12
593	Intestinal microbiota and colorectal cancer: changes in the intestinal microenvironment and their relation to the disease. **2019**, 68, 1391-1407	15
592	A survey of genes modulated by host cell infection. **2020**, 6,	8
591	A different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma	1
590	The Microbiomes of Pancreatic Tissue in Pancreatic Cancer and Non-Cancer Subjects.	1
589	Phylogeny-corrected identification of microbial gene families relevant to human gut colonization.	3
588	Fusobacterium nucleatum host cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration.	2
587	Significant and conflicting correlation of IL-9 withPrevotellaandBacteroidesin human colorectal cancer.	1
586	Integration of constraint-based modelling with faecal metabolomics reveals large deleterious effects of Fusobacteria species on community butyrate production.	0

585	The urinary microbiome associated with bladder cancer.	2
584	Microbiome-TP53 Gene Interaction in Human Lung Cancer.	1
583	Leveraging Existing 16S rRNA Gene Surveys to Identify Reproducible Biomarkers in Individuals with Colorectal Tumors.	2
582	Reevaluating the Fusobacterium Virulence Factor Landscape.	1
581	Influence of gastrectomy for gastric cancer treatment on faecal microbiome and metabolome profiles. **2020**, 69, 1404-1415	29
580	Transmission and clearance of potential procarcinogenic bacteria during fecal microbiota transplantation for recurrent Clostridioides difficile. **2019**, 4,	19
579	Analysis of Mucosa-Associated Microbiota in Colorectal Cancer. **2017**, 23, 4422-4430	30
578	Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing. **2019**, 25, 8269-8280	12
577	Colorectal Cancer Biomarkers - A New Trend in Early Diagnosis. **2018**, 44, 140-146	5
576	The microbiome in urogenital schistosomiasis and induced bladder pathologies. **2017**, 11, e0005826	28
575	The detection of the methylated Wif-1 gene is more accurate than a fecal occult blood test for colorectal cancer screening. **2014**, 9, e99233	33
574	Ubiquitous sialometabolism present among oral fusobacteria. **2014**, 9, e99263	17
573	Fusobacterium nucleatum Alters Atherosclerosis Risk Factors and Enhances Inflammatory Markers with an Atheroprotective Immune Response in ApoE(null) Mice. **2015**, 10, e0129795	27
572	Alterations of the Ileal and Colonic Mucosal Microbiota in Canine Chronic Enteropathies. **2016**, 11, e0147321	27
571	Fusobacterium nucleatum-Induced Impairment of Autophagic Flux Enhances the Expression of Proinflammatory Cytokines via ROS in Caco-2 Cells. **2016**, 11, e0165701	29
570	Mycoplasma-associated multidrug resistance of hepatocarcinoma cells requires the interaction of P37 and Annexin A2. **2017**, 12, e0184578	6
569	Streptococcus gallolyticus subsp. gallolyticus promotes colorectal tumor development. **2017**, 13, e1006440	85
568	Impact of the Microbiome on the Immune System. **2019**, 39, 313-328	12

567	Role of colonic microbiota in colorectal carcinogenesis: a systematic review. **2015**, 107, 659-71	97
566	Role of human microbiota in the development of colorectal cancer. **2019**, 9, 11-17	2
565	Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients' survival? A pilot study on relevant mechanism. **2016**, 7, 46158-46172	112
564	Clostridium difficile colonization in preoperative colorectal cancer patients. **2017**, 8, 11877-11886	17
563	Lactobacillus casei Zhang and vitamin K2 prevent intestinal tumorigenesis in mice via adiponectin-elevated different signaling pathways. **2017**, 8, 24719-24727	28
562	Invasive Fusobacterium nucleatum activates beta-catenin signaling in colorectal cancer via a TLR4/P-PAK1 cascade. **2017**, 8, 31802-31814	89
561	Potential link between Fusobacterium enrichment and DNA methylation accumulation in the inflammatory colonic mucosa in ulcerative colitis. **2017**, 8, 61917-61926	22
560	Sex-specific differences in the occurrence of subspecies and in the oral cavity. **2018**, 9, 20631-20639	6
559	Constructing personalized longitudinal holo'omes of colon cancer-prone humans and their modeling in flies and mice. **2019**, 10, 4224-4246	9
558	Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors.. **2019**, 2, 744-761	1
557	Understanding the microbiome: a primer on the role of the microbiome in colorectal neoplasia. **2020**, 33, 223-236	3
556	The Gut and Cervical Microbiome Promote Immune Activation and Response to Chemoradiation in Cervical Cancer.	2
555	The Role of Diet Related Short-Chain Fatty Acids in Colorectal Cancer Metabolism and Survival: Prevention and Therapeutic Implications. **2020**, 27, 4087-4108	42
554	Potential Impacts of Prebiotics and Probiotics in Cancer Prevention. **2020**,	4
553	Oral Microbiota Associated with Oral and Gastroenteric Cancer. **2020**, 14, 1-17	3
552	Bacterial Biofilm and its Role in the Pathogenesis of Disease. **2020**, 9,	181
551	Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation-A Special Reference to Colorectal Cancer. **2020**, 13,	8
550	Using Decision Tree Aggregation with Random Forest Model to Identify Gut Microbes Associated with Colorectal Cancer. **2019**, 10,	25

549	Visceral hypersensitive rats share common dysbiosis features with irritable bowel syndrome patients. **2016**, 22, 5211-27	25
548	Role of gut microbiota-immunity axis in patients undergoing surgery for colorectal cancer: Focus on short and long-term outcomes. **2020**, 26, 2498-2513	14
547	Tea polyphenols and their chemopreventive and therapeutic effects on colorectal cancer. **2020**, 26, 562-597	37
546	The Link between and Colon Cancer: a Fulminant Example and Review of the Evidence. **2020**, 20, e30	5
545	Prognostic Impact of Fusobacterium nucleatum Depends on Combined Tumor Location and Microsatellite Instability Status in Stage II/III Colorectal Cancers Treated with Adjuvant Chemotherapy. **2019**, 53, 40-49	24
544	<i>Fusobacterium nucleatum</i>□he Cause of Human Colorectal Cancer. **2018**, 06, 31-69	3
543	Inflammation-associated microsatellite alterations: Mechanisms and significance in the prognosis of patients with colorectal cancer. **2018**, 10, 1-14	28
542	Mining the Proteome of subsp. ATCC 25586 for Potential Therapeutics Discovery: An Approach. **2016**, 14, 255-264	2
541	Effect of Overgrowth or Decrease in Gut Microbiota on Health and Disease. **2016**, 4,	10
540	Data mining analysis of human gut microbiota links Fusobacterium spp. with colorectal cancer onset. **2019**, 15, 372-379	8
539	Linking gut microbiota with the human diseases. **2020**, 16, 196-208	14
538	Registered report: Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. **2016**, 5,	27
537	16S rRNA gene sequencing reveals effects of photoperiod on cecal microbiota of broiler roosters. **2018**, 6, e4390	11
536	promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization. **2021**, 13, 1980347	11
535	Tumorigenic bacteria in colorectal cancer: mechanisms and treatments. **2021**,	4
534	Fusobacterium Nucleatum Promotes the Development of Acute Liver Failure by Inhibiting the NAD + Salvage Metabolic Pathway.	
533	Recent Advancements in Microbiome□mmune Homeostasis and their Involvement in Cancer Immunotherapy. **2021**, 239-258	
532	Characterization of the Eukaryotic Virome of Mice from Different Sources. **2021**, 9,	0

531	Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. **2021**, 374, 216-224	28
530	Sex Variations in the Oral Microbiomes of Youths with Severe Periodontitis. **2021**, 2021, 8124593	0
529	The Regional Specificity of Mucosa-Associated Microbiota in Patients with Distal Colorectal Cancer. **2021**, 1-9	0
528	Microbiomics in Collusion with the Nervous System in Carcinogenesis: Diagnosis, Pathogenesis and Treatment. **2021**, 9,	3
527	ANGPTL4-mediated promotion of glycolysis facilitates the colonization of Fusobacterium nucleatum in colorectal cancer. **2021**,	6
526	The role of the tumor microbe microenvironment in the tumor immune microenvironment: bystander, activator, or inhibitor?. **2021**, 40, 327	6
525	Epidemiology, Molecular Mechanisms, and Clinical Trials: an Update on Research on the Association Between Red Meat Consumption and Colorectal Cancer. **2021**, 10, 435	0
524	The Intratumor Microbiota Signatures Associate With Subtype, Tumor Stage, and Survival Status of Esophageal Carcinoma. **2021**, 11, 754788	0
523	Connecting the Dots: Dietary Fat, Microbiota Dysbiosis, Altered Metabolome, and Colon Cancer. **2021**,	0
522	Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy. **2021**, 11, 710945	3
521	Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome. **2021** , 179, 114021	3
520	Dynamic impact of virome on colitis and colorectal cancer: Immunity, inflammation, prevention and treatment. **2021**,	4
519	The role played by bacterial infections in the onset and metastasis of cancer. **2021**, 2, 100078	2
518	Microbiome Crosstalk in Immunotherapy and Antiangiogenesis Therapy. **2021**, 12, 747914	3
517	Modulation of the Host Cell Transcriptome and Epigenome by Fusobacterium nucleatum. **2021**, 12, e0206221	1
516	Oral microbiota affects the efficacy and prognosis of radiotherapy for colorectal cancer in mouse models. **2021**, 37, 109886	4
515	Fulfilling the Promise of Microbiomics to Revolutionize Medicine. **2015**, 2,	
514	The Disrupted Steady-State: Tipping the Balance in Favour of Cancer. **2016**, 1-37	

513	Bacterial invasion of the pancreas revealed after analyses of the pancreatic cyst fluids.	1
512	Perturbed human sub-networks by Fusobacterium nucleatum candidate virulence proteins.	
511	FplA FromFusobacterium nucleatumis a Type Vd autotransporter phospholipase with a proposed role in altered host signaling and evasion of autophagy.	
510	Normalization of the microbiota in patients after treatment for colonic lesions.	
509	Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer.	
508	Innate Sensing by Mesenchymal TLR4/MyD88 Signals Promotes Spontaneous Intestinal Tumorigenesis.	
507	FusoPortal: An interactive repository of hybrid MinION-sequenced Fusobacterium genomes improves gene identification and characterization.	
506	Fusobacterium genomics using MinION and Illumina sequencing enables genome completion and correction.	1
505	Distinct Microbes, Metabolites, and Ecologies Define the Microbiome in Deficient and Proficient Mismatch Repair Colorectal Cancers.	
504	Gut microbiome meta-analysis reveals dysbiosis is independent of body mass index in predicting risk of obesity-associated CRC.	
503	Bacterial DNA damage effectors in host cells. **2018**, 16, 26-36	0
502	Implications of Lateral or Horizontal Gene Transfer from Bacteria to the Human Gastrointestinal System for Cancer Development and Treatment. **2019**, 377-397	0
501	Microflora analysis in the postchemotherapy patients of oral cancer. **2019**, 10, 141-145	1
500	CHAPTER 15:Nutrition, the Gastrointestinal Microbiota and Cancer Prevention. **2019**, 261-293	
499	Human Microbiome and Malignancy: Principles, Mechanisms, and Challenges. **2019**, 317-335	
498	Osteopontina, una prote□a involucrada en la progresi□ tumoral, y su participaci□ en el desarrollo del carcinoma colorrectal.. **2019**, 8, 15-21	1
497	Body Fluid Microbiome as Cancer Biomarkers. **2019**, 273-291	
496	Fecal microbiota as a non-invasive biomarker to predict the tissue iron accumulation in intestine epithelial cells and liver.	

495	Framework for rational donor selection in fecal microbiota transplant clinical trials.	0
494	Toward standards in clinical microbiome studies: comparison of three DNA extraction methods and two bioinformatic pipelines.	
493	Helminths and intestinal microbiota interaction: role in the development of noncommunicable diseases. **2019**, 18, 214-225	0
492	Characterizing the Cancer-Associated Microbiome with Small RNA Sequencing Data.	
491	Metagenomic analysis of common intestinal diseases reveals relationships among microbial signatures and powers multi-disease diagnostic models.	
490	Metagenomic Study Revealed the Potential Role of the Gut Microbiome in Gout.	
489	The virus integrations in gut microbes associated with dysbiosis of microbial community in tumorigenesis of colorectal carcinoma.	
488	Microbiota, mucosal immunity, and Colon cancer. **2020**, 157-209	
487	Colorectal cancer and the microbiome: dysplasia, probiotics, and Fusobacterium nucleatum. **2020**, 79-94	
486	Research Progress of Intestinal Flora and Tumor. **2020**, 09, 156-163	
485	Streptococcus bovis Contributes to the Development of Colorectal Cancer via Recruiting CD11b+TLR-4+ Cells. **2020**, 26, e921886	6
484	DNA glycosylase NEIL2 prevents Fusobacterium-mediated inflammation and DNA damage in colonic epithelial cells.	1
483	Diagnostic Evaluation of Streptococcus gallolyticus Infection in Patients with Colon Diseases by Polymerase Chain Reaction (PCR) and Culturing Methods. **2020**, 13,	0
482	Influence of gut and intratumoral microbiota on the immune microenvironment and anti-cancer therapy. **2021**, 174, 105966	3
481	and as Major Microbiota in Thymic Epithelial Tumors. **2021**, 11,	0
480	Bacterial Extracellular Vesicles in Gastrointestinal Tract Cancer: An Unexplored Territory. **2021**, 13,	0
479	Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management. **2021**,	16
478	Colorectal Cancer. **2020**, 1-27	

477	(M□gliche) Rolle des Mikrobioms in der Diagnostik, Therapie und Genese des Kolonkarzinoms. **2021**, 27, 195-202	0
476	L-fucose ameliorates the carcinogenic properties of in colorectal cancer. **2021**, 21, 143	1
475	Diet□microbiome interaction in colorectal cancer: a potentially discriminatory role for Fusobacterium nucleatum. **2020**, 211-241	
474	Correlation between Microbiota and Oncogenesis: Research Progress. **2020**, 10, 15-19	1
473	Role of Gut Microbiome in Colorectal Cancer. **2020**, 153-165	
472	Involvement of Oral Microbiota in the Gut Microbiota of Colorectal Cancer.	
471	Small Molecule Modulation of Microbiome Ecosystem: A Systems Pharmacology Perspective.	
470	HARMONIES: A Hybrid Approach for Microbiome Networks Inference via Exploiting Sparsity.	
469	Evolutionary dynamics in Barrett oesophagus: implications for surveillance, risk stratification and therapy. **2021**,	0
468	Gut Microbiota: A Potential Target for Cancer Interventions. **2021**, 13, 8281-8296	1
467	The oral microbiota and its role in carcinogenesis. **2021**,	7
466	Molecular and Pathology Features of Colorectal Tumors and Patient Outcomes Are Associated with and Its Subspecies. **2021**,	1
465	Faecal microbial biomarkers in early diagnosis of colorectal cancer. **2021**, 25, 10783-10797	7
464	Gut Microbiome and Gastrointestinal Diseases. **2018**, 50, 11-19	2
463	Invasion by Fusobacterium nucleatum Causes Upregulation of dll4 and klf4 Expression in Caco2 Cells.	
462	Discovering plasmids in metagenomes based on genetic architecture.	0
461	Human fecal microbiota is associated with colorectal cancer.	
460	The importance of student initiative both in and out of the lab: the second immunobiology student symposium. **2014**, 87, 73-8	

459	Role of gut microbiota in the pathogenesis of colorectal cancer; a review article. **2018**, 11, 101-109	59
458	Ancient Diet: Gut Microbiota, Immunity, and Health. **2018**, 91, 177-184	7
457	When human cells meet bacteria: precision medicine for cancers using the microbiota. **2018**, 8, 1157-1175	7
456	Detection of spp in colorectal tissue samples using reverse transcription polymerase chain reaction with minor groove binder probes: an exploratory research. **2018**, 3, e22	
455	[Oral microbiota and inflammatory bowel disease]. **2019**, 37, 443-449	1
454	[Research progress on the relationship between oral microbes and digestive system diseases]. **2018**, 36, 331-335	
453	Fusobacterium nucleatum produces cancer stem cell characteristics via EMT-resembling variations. **2020**, 13, 1819-1828	2
452	Role of microbial dysbiosis in carcinogenesis & cancer therapies. **2020**, 152, 553-561	
451	Laboratory biomarkers of an effective antitumor immune response. Clinical significance. **2021**, 29, 100489	1
450	Oral and Dental Infections: Bacteria. **2021**,	0
449	Next-generation microbial drugs developed from microbiome's natural products. **2021**, 108, 341-382	0
448	Current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy. **2021**, 145, 112443	0
447	Effect of Copper(II) Ion Binding by Porin P1 Precursor Fragments from on DNA Degradation. **2021**, 22,	0
446	Oral pathogen in the pathogenesis of colorectal cancer. **2021**,	1
445	Analysis of changes in microbiome compositions related to the prognosis of colorectal cancer patients based on tissue-derived 16S rRNA sequences. **2021**, 19, 485	0
444	Gastric Microbiota beyond : An Emerging Critical Character in Gastric Carcinogenesis. **2021**, 9,	1
443	Dietary Patterns and Associated Microbiome Changes that Promote Oncogenesis. **2021**, 9, 725821	1
442	Bacteriophages and their potential for treatment of gastrointestinal diseases. **2021**,	1

441	From Microbiome to Inflammation: The Key Drivers of Cervical Cancer. **2021**, 12, 767931	2
440	Cancer Microbiology. **2021**,	0
439	Low abundance members of the gut microbiome are potent drivers of immune cell education.	
438	A Plausible Proposition of CCL20-Related Mechanism in -Associated Oral Carcinogenesis. **2021**, 11,	1
437	Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer. **2021**, 13,	3
436	Bringing to Light the Risk of Colorectal Cancer in Inflammatory Bowel Disease: Mucosal Glycosylation as a Key Player. **2021**,	0
435	Fusobacterium nucleatum and oral cancer: a critical review. **2021**, 21, 1212	4
434	Can Periodontitis Affect the Health and Disease of the Digestive System? A Comprehensive Review of Epidemiological Evidence and Biological Mechanisms. **2021**, 8, 96	1
433	Microbiota, Bacterial Carbonic Anhydrases, and Modulators of Their Activity: Links to Human Diseases?. **2021**, 2021, 6926082	5
432	Revealing the composition of the eukaryotic microbiome of oyster spat by CRISPR-Cas Selective Amplicon Sequencing (CCSAS). **2021**, 9, 230	0
431	Microbe-based management for colorectal cancer. **2021**,	2
430	Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer. **2021**,	6
429	Onkogenese: Die Rolle der Mikrobiota.	
428	Role of microbial dysbiosis in carcinogenesis & cancer therapies. **2020**, 152, 553	3
427	drives a pro-inflammatory intestinal microenvironment through metabolite receptor-dependent modulation of IL-17 expression. **2021**, 13, 1987780	6
426	Colorectal cancer screening in IBD - can characterization of GI microbiome signatures enhance neoplasia detection?. **2022**,	1
425	Current Insights on the Modulation of Gut Microbiome and Its Effect on Human Health. **2022**, 29-51	
424	Towards a metagenomics machine learning interpretable model for understanding the transition from adenoma to colorectal cancer.. **2022**, 12, 450	2

423	The role of anaerobic bacteria in the development and prevention of colorectal cancer: A review study.. **2021**, 73, 102501	0
422	Detection of Fusobacterium nucleatum subspecies in the saliva of pre-colorectal cancer patients, using tandem mass spectrometry.. **2021**, 134, 105337	0
421	Strategies for the treatment of colorectal cancer caused by gut microbiota.. **2021**, 290, 120202	1
420	Toxicity of Pb continuous and pulse exposure on intestinal anatomy, bacterial diversity, and metabolites of Pelophylax nigromaculatus in pre-hibernation.. **2021**, 290, 133304	2
419	A review of Colorectal Cancer and Intestinal Microbiota. **2021**,	
418	Expression, Purification, and Characterization of the Recombinant, Two-Component, Response Regulator ArlR from Fusobacterium nucleatum.. **2022**, 1	
417	Biomarkers to Detect Early-Stage Colorectal Cancer.. **2022**, 10,	2
416	administration exacerbated the development of colitis-associated colorectal cancer in mice.. **2022**, 13, 124-133	6
415	Accuracy and Clinical Relevance of Intra-Tumoral Detection in Formalin-Fixed Paraffin-Embedded (FFPE) Tissue by Droplet Digital PCR (ddPCR) in Colorectal Cancer.. **2022**, 12,	
414	Fusobacterium nucleatum and Bacteroides fragilis detection in colorectal tumours: Optimal target site and correlation with total bacterial load.. **2022**, 17, e0262416	1
413	Role of probiotics and prebiotics in mitigation of different diseases.. **2022**, 96, 111602	2
412	Host microbiomes in tumor precision medicine: how far are we?. **2022**,	0
411	Potential Role of the Gut Microbiome In Colorectal Cancer Progression.. **2021**, 12, 807648	7
410	Tumor necrosis factor-□nduced protein 8-like 2 Fosters Tumor-Associated Microbiota to Promote the Development of Colorectal Cancer.. **2022**,	0
409	Bacterial infections in cancer: A bilateral relationship.. **2022**, e1771	0
408	Host tp53 mutation induces gut dysbiosis eliciting inflammation through disturbed sialic acid metabolism.. **2022**, 10, 3	0
407	Implication of Intestinal Barrier Dysfunction in Gut Dysbiosis and Diseases.. **2022**, 10,	8
406	The role of microbiota and immune system crosstalk in cancer development and therapy.. **2022**,	

405	More Than Just a Periodontal Pathogen -the Research Progress on .. **2022**, 12, 815318	2
404	The Role of Gut Microbiota in Gastrointestinal Tract Cancers.. **2022**, 70, 7	1
403	The impact of multigenerational high-fat diet feeding on the gut microbiome and host metabolism.	
402	Oral-Intestinal Microbiota in Colorectal Cancer: Inflammation and Immunosuppression.. **2022**, 15, 747-759	0
401	Gastrointestinal Microbiota Dysbiosis Associated with SARS-CoV-2 Infection in Colorectal Cancer: The Implication of Probiotics. **2022**, 13, 35-59	5
400	Gut Mucosal Microbiome Signatures of Colorectal Cancer Differ According to BMI Status.. **2021**, 8, 800566	1
399	Microbiome and colorectal carcinogenesis: Linked mechanisms and racial differences.. **2022**, 14, 375-395	2
398	Fecal signatures of Streptococcus anginosus and Streptococcus constellatus for non-invasive screening and early warning of gastric cancer.. **2022**,	1
397	Comparative Analysis of Colon Cancer-Derived Fusobacterium nucleatum Subspecies: Inflammation and Colon Tumorigenesis in Murine Models.. **2022**, e0299121	4
396	Dietary Intake Mediates Ethnic Differences in Gut Microbial Composition.. **2022**, 14,	1
395	Profiling the Bladder Microbiota in Patients With Bladder Cancer.. **2021**, 12, 718776	0
394	The impact of the human microbiome in tumorigenesis, cancer progression, and biotherapeutic development.. **2022**, 22, 53	1
393	Gut Microbiota in Colorectal Cancer: Associations, Mechanisms, and Clinical Approaches. **2022**, 6,	0
392	Hypoxia-Related Gene-Based Signature Can Evaluate the Tumor Immune Microenvironment and Predict the Prognosis of Colon Adenocarcinoma Patients.. **2021**, 14, 9853-9862	0
391	Might Cu(II) binding, DNA cleavage and radical production by YadA fragments be involved in the promotion of related cancers?. **2022**,	1
390	Growth of various obligate and facultative anaerobic intestinal bacteria in cell culture medium under aerobic and anaerobic culture conditions. **2022**,	0
389	is associated with inflammation and poor survival in early-stage HPV-negative tongue cancer.. **2022**, 4, zcac006	0
388	Identification of the Crucial Role of CCL22 in -Related Colorectal Tumorigenesis that Correlates With Tumor Microenvironment and Immune Checkpoint Therapy.. **2022**, 13, 811900	1

387	Regulation of tissue-resident memory T cells by the Microbiota.. **2022**,	1
386	promotes colorectal cancer cells adhesion to endothelial cells and facilitates extravasation and metastasis by inducing ALPK1/NF-B/ICAM1 axis.. **2022**, 14, 2038852	7
385	Novel microbiome signatures for non-invasive diagnosis of adenoma recurrence after colonoscopic polypectomy.. **2022**,	0
384	Colorectal cancer: the facts in the case of the microbiota.. **2022**, 132,	3
383	Nisin G is a novel nisin variant produced by a gut-derived Streptococcus salivarius.	1
382	promotes liver metastasis in colorectal cancer by regulating the hepatic immune niche and altering gut microbiota.. **2022**, 14,	3
381	Pro-mutagenic effects of the gut microbiota in a Lynch syndrome mouse model.. **2022**, 14, 2035660	0
380	The microbiota is a potential mediator of the crosstalk between T cells and tumors. 48-63	0
379	Fusobacterium nucleatum Promotes Colorectal Cancer Cell to Acquire Stem Cell-Like Features by Manipulating Lipid Droplet-Mediated Numb Degradation.. **2022**, e2105222	1
378	Progress in the Study of Colorectal Cancer Caused by Altered Gut Microbiota After Cholecystectomy.. **2022**, 13, 815999	1
377	and Colorectal Cancer.. **2022**, 15, 1115-1120	0
376	Roles of oral microbiota and oral-gut microbial transmission in hypertension. **2022**,	0
375	The Intestinal Microbiota May Be a Potential Theranostic Tool for Personalized Medicine.. **2022**, 12,	1
374	Affects Cell Apoptosis by Regulating Intestinal Flora and Metabolites to Promote the Development of Colorectal Cancer.. **2022**, 13, 841157	0
373	Periodontal connection with intestinal inflammation: Microbiological and immunological mechanisms.. **2022**,	1
372	Viruses, periodontitis, and comorbidities.. **2022**,	2
371	Roles of Microbiota in Cancer: From Tumor Development to Treatment.. **2022**, 2022, 3845104	0
370	The cancer chemotherapeutic 5-fluorouracil is a potent inhibitor of Fusobacterium nucleatum and its activity is modified by the intratumoral microbiota.	

369	Vanillin Derivatives Reverse -Induced Proliferation and Migration of Colorectal Cancer Through E-Cadherin/Catenin Pathway.. **2022**, 13, 841918	1
368	The association between Fusobacterium nucleatum and cancer colorectal: A systematic review and meta-analysis.. **2022**,	1
367	Roles of gut microbiota in colorectal carcinogenesis providing a perspective for early diagnosis and treatment.. **2022**,	0
366	Proposal of a health gut microbiome index based on a meta-analysis of Korean and global population datasets.. **2022**, 1	0
365	Fusobacterium nucleatum and cancer.. **2022**,	3
364	Fusobacterium nucleatum reduces METTL3-mediated mA modification and contributes to colorectal cancer metastasis.. **2022**, 13, 1248	4
363	Parvimonas micra is associated with tumour immune profiles in molecular subtypes of colorectal cancer.. **2022**, 1	0
362	Bile Acids and the Microbiome: Making Sense of This Dynamic Relationship in Their Role and Management in Crohn's Disease.. **2022**, 2022, 8416578	0
361	Exome and Tissue-Associated Microbiota as Predictive Markers of Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer.. **2022**, 12, 809441	0
360	The Microbiome: the Link to Colorectal Cancer and Research Opportunities.. **2022**, 23, 631	
359	Modulation of the extracellular matrix by Streptococcus gallolyticus subsp. gallolyticus and importance in cell proliferation.	
358	In situ imaging for tumor microbiome interactions via imaging mass cytometry on single-cell level.. **2022**,	1
357	Does the Microbiota Composition Influence the Efficacy of Colorectal Cancer Immunotherapy?. **2022**, 12, 852194	0
356	Cellular Immune Signal Exchange From Ischemic Stroke to Intestinal Lesions Through Brain-Gut Axis.. **2022**, 13, 688619	0
355	MiRKAT-MC: A Distance-Based Microbiome Kernel Association Test With Multi-Categorical Outcomes.. **2022**, 13, 841764	0
354	Skin microbiome variation with cancer progression in human cutaneous squamous cell carcinoma.. **2022**,	1
353	Appendectomy and the subsequent risk of cancer: A prospective population-based cohort study with long follow-up.. **2022**, 77, 102120	0
352	Colorectal microbiota after removal of colorectal cancer.. **2022**, 4, zcac011	1

351	Microbiome in cancer: Role in carcinogenesis and impact in therapeutic strategies.. **2022**, 149, 112898	6
350	Gut Dysbiosis and Intestinal Barrier Dysfunction: Potential Explanation for Early-Onset Colorectal Cancer.. **2021**, 11, 744606	3
349	Colorectal Cancer-Associated Microbiome Patterns and Signatures.. **2021**, 12, 787176	2
348	Alterations of the Oral Microbiota Profiles in Chinese Patient With Oral Cancer.. **2021**, 11, 780067	1
347	Human Gut Microbiota in Health and Selected Cancers.. **2021**, 22,	5
346	Crosstalk between autophagy and microbiota in cancer progression.. **2021**, 20, 163	3
345	Recent advances of fluorescent biosensors based on cyclic signal amplification technology in biomedical detection. **2021**, 19, 403	3
344	Oral and Gut Microbial Carbohydrate-Active Enzymes Landscape in Health and Disease.. **2021**, 12, 653448	2
343	Bacterial and Parasitic Pathogens as Risk Factors for Cancers in the Gastrointestinal Tract: A Review of Current Epidemiological Knowledge.. **2021**, 12, 790256	2
342	Oral Bacterial Microbiota in Digestive Cancer Patients: A Systematic Review.. **2021**, 9,	5
341	Oral Microbiota-A New Frontier in the Pathogenesis and Management of Head and Neck Cancers.. **2021**, 14,	5
340	Urine and Fecal Microbiota in a Canine Model of Bladder Cancer.	1
339	A case report of severe Fusobacterium nucleatum sepsis secondary to nephrectomy.. **2022**, 22, 309	0
338	Development and evaluation of a colorectal cancer screening method using machine learning-based gut microbiota analysis.. **2022**,	1
337	Fecal DNA Virome Is Associated with the Development of Colorectal Neoplasia in a Murine Model of Colorectal Cancer.. **2022**, 11,	1
336	The human microbiome: A coming of age story.. *Cell Host and Microbe*, **2022**, 30, 449-453	23.4
335	A Multi-Omics Study of Familial Lung Cancer: Microbiome and Host Gene Expression Patterns.. **2022**, 13, 827953	0
334	Advances in tests for colorectal cancer screening and diagnosis.. **2022**,	0

333	The Fused Methionine Sulfoxide Reductase MsrAB Promotes Oxidative Stress Defense and Bacterial Virulence in Fusobacterium nucleatum.. **2022**, e0302221	1
332	Diversity and distribution of sulfur metabolic genes in the human gut microbiome and their association with colorectal cancer.. **2022**, 10, 64	4
331	Bacteria-Mediated Oncogenesis and the Underlying Molecular Intricacies: What We Know So Far.. **2022**, 12, 836004	0
330	The gut microbial metabolite formate exacerbates colorectal cancer progression.. **2022**,	8
329	Inflammatory bowel disease and carcinogenesis.. **2022**, 1	3
328	A multi-omics machine learning framework in predicting the survival of colorectal cancer patients.. **2022**, 146, 105516	0
327	Data_Sheet_1.ZIP. **2020**,	
326	Data_Sheet_1.DOCX. **2020**,	
325	Data_Sheet_2.DOCX. **2020**,	
324	Table_1.XLSX. **2020**,	
323	Table_2.XLSX. **2020**,	
322	Table_3.XLSX. **2020**,	
321	Table_4.XLSX. **2020**,	
320	Table_5.XLSX. **2020**,	
319	Table_6.XLSX. **2020**,	
318	DataSheet_1.pdf. **2021**,	
317	Image_1.TIF. **2019**,	
316	Image_2.TIF. **2019**,	

315 Image_3.TIF. **2019**,

314 Table_1.DOCX. **2019**,

313 Table_2.DOCX. **2019**,

312 Table_3.XLSX. **2019**,

311 DataSheet_1.pdf. **2020**,

310 DataSheet_2.pdf. **2020**,

309 DataSheet_3.pdf. **2020**,

308 Image_1.tif. **2020**,

307 Image_2.tif. **2020**,

306 DataSheet_1.zip. **2020**,

305 Image_1.tif. **2020**,

304 Image_2.tif. **2020**,

303 Image_3.tif. **2020**,

302 Image_4.tif. **2020**,

301 Data_Sheet_1.ZIP. **2020**,

300 Image_1.TIF. **2020**,

299 Image_2.TIF. **2020**,

298 Image_3.JPEG. **2020**,

297 Table_1.docx. **2020**,

296 Data_Sheet_1.zip. **2019**,

295 Table_1.XLSX. **2019**,

294 Presentation_1.pdf. **2020**,

293 Presentation_1.pdf. **2019**,

292 Table_1.xlsx. **2019**,

291 Table_2.xlsx. **2019**,

290 DataSheet1.XLSX. **2018**,

289 DataSheet2.XLS. **2018**,

288 DataSheet3.DOCX. **2018**,

287 DataSheet4.XLSX. **2018**,

286 DataSheet5.XLSX. **2018**,

285 DataSheet6.DOCX. **2018**,

284 DataSheet7.DOCX. **2018**,

283 DataSheet8.DOCX. **2018**,

282 Table_1.DOCX. **2018**,

281 Image_1.pdf. **2019**,

280 Table_1.pdf. **2019**,

279	Data_Sheet_1.PDF. **2020**,	
278	Data_Sheet_2.docx. **2020**,	
277	Table_1.xlsx. **2020**,	
276	Table_2.docx. **2020**,	
275	Table_3.docx. **2020**,	
274	Image_1.png. **2020**,	
273	Table_1.docx. **2020**,	
272	Table_2.docx. **2020**,	
271	Data_Sheet_1.docx. **2019**,	
270	Data_Sheet_2.docx. **2019**,	
269	Data_Sheet_3.docx. **2019**,	
268	Image_1.tif. **2020**,	
267	Image_2.tif. **2020**,	
266	Image_3.tif. **2020**,	
265	Microbiota in health and diseases.. **2022**, 7, 135	28
264	[Changes in the structure of intestinal mucosal flora in colorectal cancer patients].. **2022**, 42, 263-271	0
263	The Influence of Nutrition on Intestinal Permeability and the Microbiome in Health and Disease.. **2022**, 9, 718710	1
262	Prediction of Pathogenic Factors in Dysbiotic Gut Microbiomes of Colorectal Cancer Patients Using Reverse Microbiomics.. **2022**, 12, 882874	1

261	Effects of cage versus floor rearing system on goose intestinal histomorphology and cecal microbial composition. **2022**, 101931	0
260	Berberine as a Potential Agent for the Treatment of Colorectal Cancer.. **2022**, 9, 886996	1
259	Fusobacterium nucleatum promotes colon cancer progression by changing the mucosal microbiota and colon transcriptome in a mouse model. **2022**, 28, 1981-1995	0
258	Anaerobic bloodstream infections in Italy (ITANAEROBY): A 5-year retrospective nationwide survey.. **2022**, 102583	1
257	Candida albicans evades NK cell elimination via binding of Agglutinin-Like Sequence proteins to the checkpoint receptor TIGIT.. **2022**, 13, 2463	2
256	Autoimmunity and Cancer□wo Sides of the Same Coin. **2022**, 13,	1
255	Diagnostic and Therapeutic Uses of the Microbiome in the Field of Oncology. **2022**,	
254	Periodontitis pathogen promotes pancreatic tumorigenesis via neutrophil elastase from tumor-associated neutrophils.. **2022**, 14, 2073785	0
253	The Lumenal Microbiota Varies Biogeographically in the Gastrointestinal Tract of Rhesus Macaques.. **2022**, e0034322	1
252	Microbiome and Development of Ovarian Cancer.. **2022**,	
251	The Gut Microbiome in Colorectal Cancer.. **2022**,	
250	Subchronic Toxicity of Microcystin-LR on Young Frogs (Xenopus laevis) and Their Gut Microbiota. **2022**, 13,	
249	The role of microbiota in colorectal cancer.. **2022**, 1	
248	Relationship between gut microbiota and colorectal cancer: Probiotics as a potential strategy for prevention. **2022**, 156, 111327	3
247	The Potential of the Gut Microbiome to Reshape the Cancer Therapy Paradigm: A Review.. **2022**,	3
246	Association of the gut microbiome with cancer immunotherapy.. **2022**, 1	
245	Recent advances in bacteriophage-based therapeutics: Insight into the post-antibiotic era. **2022**,	0
244	Cancer-Associated Microbiota: From Mechanisms of Disease Causation to Microbiota-Centric Anti-Cancer Approaches. **2022**, 11, 757	2

243	Prognostic and clinicopathological significance of Fusobacterium nucleatum in colorectal cancer: a systemic review and meta-analysis.. **2022**, 56, 144-151	0
242	Colon Tumors in Enterotoxigenic Bacteroides fragilis (ETBF)-Colonized Mice Do Not Display a Unique Mutational Signature but Instead Possess Host-Dependent Alterations in the APC Gene.. **2022**, e0105522	2
241	Technologies for Identification and Validation of Cancer Biomarkers. **2022**, 27-64	
240	Microbial Dysbiosis in Oral Cancer. **2022**, 95-106	
239	Association of Gut Microbiota and Biochemical Features in a Chinese Population With Renal Uric Acid Stone. 13,	0
238	Microbiota in Tumors: From Understanding to Application. 2200470	2
237	Microbiome Analysis in Patients with Colorectal Cancer by 16S Ribosomal RNA Sequencing in the Southeast of Iran. **2022**, 15,	0
236	Colon Cancer: From Epidemiology to Prevention. **2022**, 12, 499	0
235	The Microbiome in Pancreatic Cancer-Implications for Diagnosis and Precision Bacteriophage Therapy for This Low Survival Disease. **2022**, 12,	
234	Intratumor microbiome in cancer progression: current developments, challenges and future trends. **2022**, 10,	0
233	Fecal microbiota and bile acids in IBD patients undergoing screening for colorectal cancer. **2022**, 14,	0
232	Metabolic reprogramming: a bridge between aging and tumorigenesis.	1
231	Gut Microbiota Signatures in Tumor, Para-Cancerous, Normal Mucosa, and Feces in Colorectal Cancer Patients. **2022**, 10,	2
230	Detection of Fusobacterium nucleatum DNA in primary care patient stool samples does not predict progression of colorectal neoplasia. **2022**, 17, e0269541	
229	Bacteria and tumor: Understanding the roles of bacteria in tumor genesis and immunology. **2022**, 261, 127082	0
228	Microbiome and Cancer Metastasis. **2022**, 767-773	
227	Oral Microbiota, a Potential Determinant for the Treatment Efficacy of Gastric Helicobacter pylori Eradication in Humans. **2022**, 71, 227-239	0
226	The Emerging Roles of Human Gut Microbiota in Gastrointestinal Cancer. 13,	0

225	Alterations in co-abundant bacteriome in colorectal cancer and its persistence after surgery: a pilot study. **2022**, 12,	0
224	Construction of size-transformable supramolecular nano-platform against drug-resistant colorectal cancer caused by Fusobacterium nucleatum. **2022**, 137605	1
223	Implications of Gut Microbiota in Epithelial Mesenchymal Transition and Cancer Progression: A Concise Review. **2022**, 14, 2964	1
222	Role of the microbiome in oral cancer occurrence, progression and therapy. **2022**, 105638	0
221	Sequence Divergence in the Arginase Domain of Ornithine Decarboxylase/Arginase in Fusobacteriacea Leads to Loss of Function in Oral Associated Species.	
220	Meta-analysis of mucosal microbiota reveals universal microbial signatures and dysbiosis in gastric carcinogenesis.	0
219	The role of gut microbiota in the development of colorectal cancer: a review.	2
218	Effect of gut microbiota in the colorectal cancer and potential target therapy. **2022**, 13,	0
217	Gut Microbial Profile in Patients with Pancreatic Cancer. **2022**, 15,	
216	The stimulatory effect of fusobacteria on dendritic cells under aerobic or anaerobic conditions. **2022**, 12,	
215	Gut Microbiota Characteristics Are Associated With Severity of Acute Radiation-Induced Esophagitis. 13,	0
214	Fusobacterium nucleatum promotes the development of acute liver failure by inhibiting the NAD+ salvage metabolic pathway. **2022**, 14,	
213	Fusobacterium nucleatum and Malignant Tumors of the Digestive Tract: A Mechanistic Overview. **2022**, 9, 285	1
212	Pragmatic Expectancy on Microbiota and Non-Small Cell Lung Cancer: A Narrative Review. **2022**, 14, 3131	0
211	Human Colon Cancer Derived Clostridioides difficile Strains Drive Colonic Tumorigenesis in Mice. OF1-OF13	3
210	Meta-analysis of fecal metagenomes reveals global viral signatures and its diagnostic potential for colorectal cancer and adenoma.	
209	NF- B Regulation by Gut Microbiota Decides Homeostasis or Disease Outcome During Ageing. 10,	1
208	Integrated analysis of colorectal cancer reveals cross-cohort gut microbial signatures and associated serum metabolites. **2022**,	0

207	Comparison of two primer-probe sets of Fusobacterium nucleatum using droplet digital polymerase chain reaction for the detection of colorectal neoplasia from faecal samples. 000456322211155	
206	The triple interactions between gut microbiota, mycobiota and host immunity. 1-21	0
205	Inflammation, microbiome and colorectal cancer disparity in African-Americans: Are there bugs in the genetics?. **2022**, 28, 2783-2801	
204	Inflammation, microbiome and colorectal cancer disparity in African-Americans: Are there bugs in the genetics?. **2022**, 28, 2782-2801	0
203	Cancer as microenvironmental, systemic and environmental diseases: opportunity for transdisciplinary microbiomics science. gutjnl-2022-327209	4
202	The Tissue-Associated Microbiota in Colorectal Cancer: A Systematic Review. **2022**, 14, 3385	0
201	An international report on bacterial communities in esophageal squamous cell carcinoma.	1
200	Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1). **2022**, 31, 100813	1
199	Biofilm competency of Desulfovibrio vulgaris Hildenborough facilitates colonization in the gut and represses adenoma development in a rat model of colon cancer.	
198	Effect of a bacteriocin-producing Streptococcus salivarius on the pathogen Fusobacterium nucleatum in a model of the human distal colon. **2022**, 14,	0
197	The Role of the Microbiome in Pancreatic Oncogenesis.	0
196	The microbiome, immunity, anaerobism, and inflammatory conditions: a multifaceted systems biology intervention. **2022**, 205-216	
195	Interaction between microbiota and immunity and its implication in colorectal cancer. 13,	0
194	Parvimonas micra promotes colorectal tumorigenesis and is associated with prognosis of colorectal cancer patients.	4
193	Microbiota and lung cancer. **2022**,	2
192	Gut microbiome in colorectal cancer: Clinical diagnosis and treatment. **2022**,	0
191	Versatile Triad Alliance: Bile Acid, Taurine and Microbiota. **2022**, 11, 2337	0
190	DNA methyltransferase enhanced Fusobacterium nucleatum genetics.	

189	Low abundance members of the gut microbiome exhibit high immunogenicity. **2022**, 14,	0
188	Butyrate-producing Eubacterium rectale suppresses lymphomagenesis by alleviating the TNF-induced TLR4/MyD88/NF-B axis. **2022**, 30, 1139-1150.e7	2
187	Microbial Proteins in Stomach Biopsies Associated with Gastritis, Ulcer, and Gastric Cancer. **2022**, 27, 5410	1
186	Colorectal Cancer in Ulcerative Colitis: Mechanisms, Surveillance and Chemoprevention. **2022**, 29, 6091-6114	0
185	Involvement of Fusobacterium nucleatum in malignancies except for colorectal cancer: A literature review. 13,	2
184	Human microbiota colonization and pancreatic ductal carcinoma. 1-14	
183	New insights into natural products that target the gut microbiota: Effects on the prevention and treatment of colorectal cancer. 13,	0
182	Pan-cancer analysis of microbiome quantitative trait loci.	0
181	Extremely small and incredibly close: Gut microbes as modulators of inflammation and targets for therapeutic intervention. 13,	
180	Metagenome-scale community metabolic modelling for understanding the role of gut microbiota in human health. **2022**, 105997	0
179	Live Biotherapeutic Lactococcus lactis GEN3013 Enhances Antitumor Efficacy of Cancer Treatment via Modulation of Cancer Progression and Immune System. **2022**, 14, 4083	0
178	Oral microbiome and serological analyses on association of Alzheimer disease and periodontitis.	0
177	Targeting microbiota-host interactions with resveratrol on cancer: Effects and potential mechanisms of action. 1-23	0
176	Local Breast Microbiota: A New Player on the Block. **2022**, 14, 3811	1
175	Periodontal disease and cancer risk: A nationwide population-based cohort study. 12,	
174	Biological roles of toll-like receptors and gut microbiota in colorectal cancer. **2022**, 17, 1071-1089	
173	Microbiota-driven mechanisms at different stages of cancer development. **2022**, 32, 100829	1
172	KCNJ14 knockdown significantly inhibited the proliferation and migration of colorectal cells. **2022**, 15,	0

171	The complex immunological role of Helicobacter in modulating cancer. **2022**, 43, 826-832	0
170	Healthy gut microbiome in the prevention of colorectal cancer. **2022**, 315-328	0
169	Role of the microbiome in the function and diseases of the digestive system. **2022**, 93-105	0
168	The redox-active Cu-FomA complex: the mode that provides coordination of CuII/CuI ions during the reduction/oxidation cycle.	0
167	An overview of cancer and the human microbiome. **2022**,	0
166	Infectious Causes of Neoplasia in the Domestic Cat. **2022**, 9, 467	1
165	Identification of oral bacteria in the gut and foot ulcer of patients with diabetes mellitus □A secondary analysis of whole-metagenome and meta-transcriptomic microbiome data.	0
164	Global trends in research on miRNA□microbiome interaction from 2011 to 2021: A bibliometric analysis. 13,	0
163	The Microbiome-Immune Axis Therapeutic Effects in Cancer Treatments. **2022**, 32, 1086-1097	0
162	Biofilm competency of Desulfovibrio vulgaris Hildenborough facilitates colonization in the gut and represses adenoma development in a rat model of colon cancer.	0
161	Integrative analysis of the mouse fecal microbiome and metabolome reveal dynamic phenotypes in the development of colorectal cancer. 13,	0
160	Small molecule modulation of microbiota: a systems pharmacology perspective. **2022**, 23,	0
159	Fusobacterium nucleatum promotes proliferation in oesophageal squamous cell carcinoma via AHR / CYP1A1 signalling.	1
158	Microbiota manipulation to increase macrophage IL-10 improves colitis and limits colitis-associated colorectal cancer. **2022**, 14,	1
157	Correlation of PLVAP protein expression with microbial composition, clinicopathological features and prognosis of patients with stomach adenocarcinoma.	0
156	Inflammation-associated nitrate facilitates ectopic colonization of oral bacterium Veillonella parvula in the intestine. **2022**, 7, 1673-1685	2
155	Microbes Contribute to Chemopreventive Efficacy, Intestinal Tumorigenesis and the Metabolome.	0
154	Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer. **2022**,	2

153	Iron accelerates Fusobacterium nucleatum-induced CCL8 expression in macrophages and is associated with colorectal cancer progression.	0
152	Clinical implications of the oral-gut microbiome axis and its association with colorectal cancer (Review). **2022**, 48,	0
151	Effect of Tenofovir on gut microbiota and inflammatory factors in HBV-infected individuals.	0
150	Alterations to the duodenal microbiota are linked to gastric emptying and symptoms in functional dyspepsia. gutjnl-2021-326158	1
149	The Microbiome in Gastrointestinal Cancers. **2022**, 51, 667-680	0
148	Modulation of the extracellular matrix by Streptococcus gallolyticus subsp. gallolyticus and importance in cell proliferation. **2022**, 18, e1010894	0
147	Mendelian randomization analyses reveal causal relationships between the human microbiome and longevity.	0
146	Nutrition and Microbiome Interactions in Human Cancer. **2022**,	0
145	Microbiome epidemiology and association studies in human health.	0
144	The evolution of modern notions about bladder cancer. **2022**, 26, 57-64	0
143	Meta-analysis of fecal viromes demonstrates high diagnostic potential of the gut viral signatures for colorectal cancer and adenoma risk assessment. **2022**,	1
142	Immunotherapy-based novel nanoparticles in the treatment of gastrointestinal cancer: Trends and challenges. 28, 5403-5419	0
141	Role of microbiota and microbiota-derived short-chain fatty acids in PDAC.	0
140	Targeting the gut microbiota for cancer therapy.	2
139	The Role of Fusobacterium nucleatum in Colorectal Cancer Cell Proliferation and Migration. **2022**, 14, 5350	0
138	Altered Gut Microbial Profile Accompanied by Abnormal Fatty Acid Metabolism Activity Exacerbates Endometrial Cancer Progression.	0
137	Circulating IgA antibodies against the Fusobacterium nucleatum adhesin FadA are a potential biomarker for colorectal neoplasia.	0
136	Periodontitis and Its Inflammatory Changes Linked to Various Systemic Diseases: A Review of Its Underlying Mechanisms. **2022**, 10, 2659	0

135	Relative enrichment of oral bacteria in feces indicates loss of intestinal commensals with implications for host health.	0
134	THE IMPACT OF BARIATRIC SURGERY ON COLORECTAL CANCER RISK. **2022**,	0
133	The influence of machine learning technologies in gut microbiome research and cancer studies - A review. **2022**, 121118	0
132	Clinical Significance of Fusobacterium nucleatum and Microsatellite Instability in Evaluating Colorectal Cancer Prognosis. Volume 14, 3021-3036	0
131	Fusobacterium and Colorectal Cancer: Important Association or Random Coincidence?. **2022**, 82, 3671-3672	0
130	Enrichment of Prevotella intermedia in human colorectal cancer and its additive effects with Fusobacterium nucleatum on the malignant transformation of colorectal adenomas. **2022**, 29,	1
129	Isolation and characterization of novel Fusobacterium nucleatum bacteriophages. 13,	0
128	Enhanced Fusobacterium nucleatum Genetics Using Host DNA Methyltransferases To Bypass Restriction-Modification Systems.	0
127	Microbiome analysis reveals universal diagnostic biomarkers for colorectal cancer across populations and technologies. 13,	0
126	The Influence of the Gut Microbiome in Paediatric Cancer Origin and Treatment. **2022**, 11, 1521	0
125	The difference of human gut microbiome in colorectal cancer with and without metastases. 12,	0
124	The intestinal microbiota in colorectal cancer metastasis Passive observer or key player?. **2022**, 180, 103856	0
123	Interaction of microbiome and immunity in tumorigenesis and clinical treatment. **2022**, 156, 113894	0
122	Fusobacterium nucleatum stimulates cell proliferation and promotes PD-L1 expression via IFIT1-related signal in colorectal cancer. **2023**, 35, 100850	0
121	Characterizing microbiota and metabolomics analysis to identify candidate biomarkers in lung cancer. 12,	0
120	Compartmentalization of the host microbiome: how tumor microbiota shapes checkpoint immunotherapy outcome and offers therapeutic prospects. **2022**, 10, e005401	0
119	Fusobacterium nucleatum and its associated systemic diseases: epidemiologic studies and possible mechanisms. **2023**, 15,	1
118	The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota. **2022**, 41, 111625	1

117	Nitroreductase-instructed supramolecular assemblies for microbiome regulation to enhance colorectal cancer treatments. **2022**, 8,	0
116	Clinicopathological differences of high Fusobacterium nucleatum levels in colorectal cancer: A review and meta-analysis. 13,	0
115	Antibiotics, the microbiome and gastrointestinal cancers: A causal interference?. **2022**, 67, 102315	0
114	Metformin abrogates Fusobacterium nucleatum-induced chemoresistance in colorectal cancer by inhibiting miR-361-5p/sonic hedgehog signaling-regulated stemness.	0
113	The effect of the intratumoral microbiome on tumor occurrence, progression, prognosis and treatment. 13,	1
112	Increased D-Neopterin biosynthesis in gut microbiome promoted colonic carcinogenesis after ampicillin or amoxicillin treatment.	0
111	Intratumoral bacteria are an important □accomplice□ in tumor development and metastasis. **2023**, 1878, 188846	0
110	The effect of microbiome composition on impulsive and violent behavior: A systematic review. **2023**, 440, 114266	1
109	Targeting emerging cancer hallmarks by transition metal complexes: Cancer stem cells and tumor microbiome. Part I. **2023**, 477, 214923	0
108	Fusobacterium nucleatum and colorectal cancer: From phenomenon to mechanism. 12,	0
107	Tumor microbiome □an integral part of the tumor microenvironment. 12,	1
106	Predictive biomarkers of colon cancer immunotherapy: Present and future. 13,	3
105	Intratumoral microbiome and gastrointestinal cancers. 12,	0
104	Understanding and harnessing triple-negative breast cancer-related microbiota in oncology. 12,	0
103	Patients with Increased Levels of Fusobacterium Tumoral Abundance are Associated with Better Outcomes in Mucinous Colorectal Cancer..	0
102	Enterotypical Prevotella and three novel bacterial biomarkers in preoperative stool predict the clinical outcome of colorectal cancer. **2022**, 10,	0
101	Domestic Cooking Affects the Prebiotic Performances of Chinese Yam. **2022**, 11, 3794	0
100	Implication of gut microbes and its metabolites in colorectal cancer.	1

99	Influence of Lactobacillus reuteri , Bifidobacterium animalis subsp. lactis , and prebiotic inulin on dysbiotic dental biofilm composition ex vivo.	0
98	Investigation of putative roles of smoking-associated salivary microbiome alterations on carcinogenesis by integrative in silico analysis. **2022**, 107805	0
97	Therapeutic Target Identification and Inhibitor Screening against Riboflavin Synthase of Colorectal Cancer Associated Fusobacterium nucleatum. **2022**, 14, 6260	0
96	Elevated Dietary Carbohydrate and Glycemic Intake Associate with an Altered Oral Microbial Ecosystem in Two Large U.S. Cohorts. **2022**, 2, 1558-1568	0
95	Factors that influence the pancreatic and duodenal microbiome in patients undergoing pancreatic surgery. **2022**, 17, e0278377	0
94	Urine and fecal microbiota in a canine model of bladder cancer and comparison of canine and human urine microbiota. **2022**, 15, 1245-1263	0
93	Relationship between gut microbiota and prognosis, clinical characteristics of colorectal cancer based on 16S rRNA sequencing.	0
92	The Oral-Gut Axis: Periodontal Diseases and Gastrointestinal Disorders.	1
91	Mediation effect of intestinal microbiota on the relationship between fiber intake and colorectal cancer.	0
90	Microbiota and their metabolites potentiate cancer immunotherapy: Therapeutic target or resource for small molecule drug discovery?. 13,	0
89	Role of oral microbiome in oral oncogenesis, tumor progression, and metastasis.	0
88	Sodium New Houttuyfonate Inhibits Cancer-Promoting Fusobacterium nucleatum (Fn) to Reduce Colorectal Cancer Progression. **2022**, 14, 6111	1
87	Oral Microbiome in Nonsmoker Patients with Oral Cavity Squamous Cell Carcinoma, Defined by Metagenomic Shotgun Sequencing. **2022**, 14, 6096	0
86	The Colloquy between Microbiota and the Immune System in Colon Cancer: Repercussions on the Cancer Therapy. **2022**, 28, 3478-3485	0
85	Integrated omics analysis reveals the immunologic characteristics of cystic Peyer patches in the cecum of Bactrian camels. 11, e14647	0
84	Fecal and Tissue Microbiota Are Associated with Tumor T-Cell Infiltration and Mesenteric Lymph Node Involvement in Colorectal Cancer. **2023**, 15, 316	0
83	Animal Models in the Study of Microbiome in Gastrointestinal Cancer. **2023**, 181-192	0
82	Research trends on the relationship between gut microbiota and colorectal cancer: A bibliometric analysis. 12,	0

81	Radiomics Approaches for the Prediction of Pathological Complete Response after Neoadjuvant Treatment in Locally Advanced Rectal Cancer: Ready for Prime Time?. **2023**, 15, 432	0
80	Targeting Gut Microbiota in Colorectal Cancer. **2023**, 251-267	0
79	Microbiome, immune system and cancer: three sides of the one medal. **2023**, 21, 131-144	0
78	Intratumor microbiota: a novel tumor component.	0
77	Intratumour Fusobacterium nucleatum and immune response to oesophageal cancer.	0
76	Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy. **2023**, 8,	0
75	Metabolically-targeted dCas9 expression in bacteria.	0
74	Microbiome in Colorectal Cancer. **2023**, 23-39	0
73	Optimized Antimicrobial Peptide Jelleine-I Derivative Br-J-I Inhibits Fusobacterium Nucleatum to Suppress Colorectal Cancer Progression. **2023**, 24, 1469	1
72	The role of Fusobacteria in oral cancer and immune evasion. Publish Ahead of Print,	0
71	Gut Microbiome in Health and Gastrointestinal Cancer. **2023**, 5-21	0
70	Gut Microbiota and Breast Cancer: The Dual Role of Microbes. **2023**, 15, 443	1
69	Bacterial Translocation to the Mesentery. **2023**, 93-109	0
68	Gut Microbiota Modulation: Probiotics and Prebiotics in GI Cancer. **2023**, 201-236	0
67	Emerging avenues linking myeloid-derived suppressor cells to periodontal disease. **2023**,	0
66	Role of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer.	0
65	The oral cancer microbiome contains tumor space□pecific and clinicopathology-specific bacteria. 12,	0
64	Mendelian randomization study of causal link from gut microbiota to colorectal cancer. **2022**, 22,	1

63	Multi-Fold Computational Analysis to Discover Novel Putative Inhibitors of Isethionate Sulfite-Lyase (Isla) from Bilophila wadsworthia: Combating Colorectal Cancer and Inflammatory Bowel Diseases. **2023**, 15, 901	0
62	Role of Bacteria in the Development of Colorectal Cancer.	0
61	The Influence of the Microbiome on Metastatic Colorectal Cancer.	0
60	Research Progress of Intestinal Microecology in the Pathogenesis of Colorectal Adenoma and Carcinogenesis. **2023**, 22, 153303382211359	0
59	The Microbiome-TIME Axis: A Host of Possibilities. **2023**, 11, 288	0
58	Understanding the role of the gut microbiome in gastrointestinal cancer: A review. 14,	0
57	Immunotherapy combined with radiotherapy to reverse immunosuppression in microsatellite stable colorectal cancer.	0
56	A new anti-colon cancer tumor pathway of Phenyllactic acid by reducing adhesion of Fusobacterium nucleatum. 43,	0
55	Enrichment of oral-derived bacteria in inflamed colorectal tumors and distinct associations of Fusobacterium in the mesenchymal subtype. **2023**, 100920	0
54	Gut microbial metabolites and colorectal cancer. **2023**, 353-373	0
53	Defining the Role of the Gut Microbiome in the Pathogenesis and Treatment of Lymphoid Malignancies. **2023**, 24, 2309	0
52	Microbiome and spatially resolved metabolomics analysis reveal the anticancer role of gut Akkermansia muciniphila by crosstalk with intratumoral microbiota and reprogramming tumoral metabolism in mice. **2023**, 15,	0
51	Pathological significance of Heme Oxygenase-1 as a potential tumor promoter in heme-induced colorectal carcinogenesis. **2023**,	0
50	Molecular principles of tissue invasion and metastasis. **2023**, 324, C971-C991	0
49	From adenoma to CRC stages: the oral-gut microbiome axis as a source of potential microbial and metabolic biomarkers of malignancy. **2023**, 40, 100901	0
48	The Influence of the microbiome on the innate immune microenvironment of solid tumors. **2023**, 37, 100878	0
47	Metformin Regulates Gut Microbiota Abundance to Suppress M2 Skewing of Macrophages and Colorectal Tumorigenesis in Mice. **2023**, 61, 109-120	0
46	Gut Microbiota in Colorectal Cancer: Biological Role and Therapeutic Opportunities. **2023**, 15, 866	0

45	Bacteria and macrophages in the tumor microenvironment. 14,	0
44	Opisthorchis viverrini, Clonorchis sinensis and Opisthorchis felineus liver flukes affect mammalian host microbiome in a species-specific manner. **2023**, 17, e0011111	0
43	Analysis of the cervical microbiome in women from the German national cervical cancer screening program.	0
42	The Efficacy and Mechanism of Qinghua Jianpi Recipe in Inhibiting Canceration of Colorectal Adenoma Based on Inflammatory Cancer Transformation. **2023**, 2023, 1-19	0
41	The diagnostic and prognostic potential of gut bacteria in inflammatory bowel disease. **2023**, 15,	1
40	Progress of gut microbiome and its metabolomics in early screening of colorectal cancer.	1
39	The interaction between innate immunity and oral microbiota in oral diseases. **2023**, 19, 405-415	0
38	The Debate between the Human Microbiota and Immune System in Treating Aerodigestive and Digestive Tract Cancers: A Review. **2023**, 11, 492	0
37	The Gut-Prostate Axis: A New Perspective of Prostate Cancer Biology through the Gut Microbiome. **2023**, 15, 1375	0
36	Cell Surface Fibroblast Activation Protein-2 (Fap2) of Fusobacterium nucleatum as a Vaccine Candidate for Therapeutic Intervention of Human Colorectal Cancer: An Immunoinformatics Approach. **2023**, 11, 525	0
35	Advances in research on the effectiveness and mechanism of Traditional Chinese Medicine formulas for colitis-associated colorectal cancer. 14,	0
34	MiRNAs as epigenetic regulators for gut microbiome. **2023**, 153-172	0
33	Seminars in immunology special issue: Nutrition, microbiota and immunity The unexplored microbes in health and disease. **2023**, 66, 101735	0
32	The Impact of Gut Microbiota-Derived Metabolites on the Tumor Immune Microenvironment. **2023**, 15, 1588	0
31	Interaction of gut microbiota with the tumor microenvironment: A new strategy for antitumor treatment and traditional Chinese medicine in colorectal cancer. 10,	0
30	PLVAP protein expression correlated with microbial composition, clinicopathological features, and prognosis of patients with stomach adenocarcinoma.	0
29	Tissue-resident Lachnospiraceae family bacteria protect against colorectal carcinogenesis by promoting tumor immune surveillance. **2023**, 31, 418-432.e8	0
28	Intestinal flora plays a role in the progression of hepatitis-cirrhosis-liver cancer. 13,	0

27	Fusobacterium nucleatum -induced exosomal HOTTIP promotes gastric cancer progression through the microRNA -885-3p/ EphB2 axis.	0
26	Tumor-Targeting Nanoassembly for Enhanced Colorectal Cancer Therapy by Eliminating Intratumoral Fusobacterium nucleatum.	0
25	Global research on the crosstalk between intestinal microbiome and colorectal cancer: A visualization analysis. 13,	0
24	Isolation ofFusobacterium nucleatumfrom human feces using immunomagnetic separation coupled with fastidious anaerobe agar. **2023**, 134,	0
23	Intestinal bacteria and colorectal cancer: etiology and treatment. **2023**, 15,	0
22	Molecular Pathways of Carcinogenesis in Familial Adenomatous Polyposis. **2023**, 24, 5687	0
21	Ligature-Induced Periodontitis Drives Colorectal Cancer: An Experimental Model in Mice. 002203452311582	0
20	Intestinal Microbiomes In Gastrointestinal Cancer. 36, 269-275	0
19	Microbiome-Induced Autoimmunity and Novel Therapeutic Intervention. **2023**, 71-90	0
18	Implication of Obesity and Gut Microbiome Dysbiosis in the Etiology of Colorectal Cancer. **2023**, 15, 1913	0
17	Fecal Microbiota Transplantation as a Cancer Therapeutic. **2023**, 29, 102-108	0
16	Intestinal Microbiomics in Physiological and Pathological Conditions.	0
15	Diet-gut microbial interactions influence cancer immunotherapy. 13,	0
14	Synbiotics in Gastric Cancer. **2023**, 157-173	0
13	Microbial composition of tumorous and adjacent gastric tissue is associated with prognosis of gastric cancer. **2023**, 13,	0
12	Meta-analyses of host metagenomes from colorectal cancer patients reveal strong relationship between colorectal cancer-associated species.	0
11	Antibodies to oral pathobionts and colon cancer risk in the CLUE I cohort study.	0
10	Mendelian randomization analyses reveal causal relationships between the human microbiome and longevity. **2023**, 13,	0

9	Gingival Squamous Cell Carcinoma Predicted to Originate From the Gingival Sulcular Epithelium in a Young Female: A Report of a Rare Case. **2023**,	0
8	Keystone pathobionts associated with colorectal cancer promote oncogenic reprograming.	0
7	Forging the microbiome to help us live long and prosper. **2023**, 21, e3002087	0
6	Autoimmunity and Carcinogenesis: Their Relationship under the Umbrella of Autophagy. **2023**, 11, 1130	0
5	Development and treatment of colorectal cancer: Insights from multi-kingdom microbiota. **2023**, 4, 21-40	0
4	Advances in the Utilization of Zebrafish for Assessing and Understanding the Mechanisms of Nano-/Microparticles Toxicity in Water. **2023**, 11, 380	0
3	Increasing the accuracy of colorectal cancer screening. 1-9	0
2	A Probiotic Formula for Modulation of Colorectal Cancer Risk via Reducing CRC-Associated Bacteria. **2023**, 12, 1244	0
1	Awareness of intratumoral bacteria and their potential application in cancer treatment. **2023**, 14,	0